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 Chronic pain and depression are widespread and debilitating diseases that, for many 
people, cannot be adequately addressed with current treatment options. Delta opioid receptor 
(DOR) agonists have been proposed as novel treatments for these disorders. DOR is a member of 
the opioid receptor family of G protein-coupled receptors (GPCRs). DOR signals through 
inhibitory Gαi/o proteins that are negatively regulated by regulator of G protein signaling (RGS) 
proteins. Activation of DOR induces antihyperalgesia and antidepressant-like effects in animal 
models without the constipation, respiratory depression, and abuse liability associated with mu 
opioid receptor agonists such as morphine. Unfortunately, some DOR agonists cause 
convulsions, hindering their development as therapeutics in humans. The experiments described 
in this thesis sought to further characterize the intracellular signaling pathways and mechanisms 
underlying DOR-mediated behaviors. Specifically, these studies used a number of mouse models 
to determine differences in the regulation of DOR-mediated convulsions relative to the 
antihyperalgesic and antidepressant-like effects of DOR agonists. Antihyperalgesia was 
measured in a nitroglycerin-induced thermal hyperalgesia assay. Antidepressant-like effects were 
evaluated in the forced swim and tail suspension tests. Mice were also observed for convulsive 
activity post-agonist treatment. 
 To assess the role of G protein signaling in DOR-mediated behaviors, we compared 
behaviors induced by the DOR agonist SNC80 in RGS4 knockout, Gαo RGS-insensitive (RGSi) 
knock-in, and Gαo knockout mice. SNC80-induced antihyperalgesia was enhanced in RGS4 
knockout and Gαo RGSi mice. SNC80-induced antidepressant-like effects were also potentiated 
in both RGS4 knockout and Gαo RGSi mice. However, SNC80-induced convulsions were not 
changed in either strain. In Gαo heterozygous knockout mice, SNC80-induced antihyperalgesia 
was abolished while the antidepressant-like effects and convulsions were unaltered. Taken 
together, these data demonstrate that DOR-mediated antihyperalgesia and antidepressant-like 
effects, but not convulsions, are regulated by Gαo and RGS4.
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 To further characterize the pharmacological properties mediating behavioral outcomes of 
DOR agonists, we compared the behavioral effects of SNC80 with those of the DOR partial 
agonist BU48. BU48 produced convulsions with similar potency to SNC80. BU48 also produced 
antidepressant-like effects with reduced potency relative to SNC80 and failed to elicit 
antihyperalgesia. These results suggest that the efficacy requirement for DOR-mediated 
convulsions may be low relative to other DOR-mediated behaviors. The efficacy requirements 
for DOR-mediated behaviors were further evaluated by comparing the shifts in the SNC80 dose 
response curves for each of these behaviors following decreases in DOR receptor reserve. 
Decreases in receptor reserve were produced using DOR heterozygous knockout mice as well as 
by treating mice with the DOR irreversible antagonist naltrindole-5’-isothiocyanate (5’-NTII). 
SNC80-induced antihyperalgesia displayed the largest potency shift in DOR heterozygous and 
5’-NTII treated mice. Antidepressant-like effects displayed the next largest shift followed by 
convulsions. These findings suggest that DOR-mediated behaviors display the following rank 
order of efficacy requirement: convulsions < antidepressant like effects < antihyperalgesia. 
Furthermore, the DOR competitive antagonist naltrindole differentially shifted the SNC80 dose 
response curves of these behaviors, suggesting that different DOR receptor populations may 
mediate these behaviors. 
Overall, the work presented in this thesis suggests that DOR-mediated behaviors are 
generated by distinct signaling mechanisms and receptor populations. The possibility of 
pharmacologically targeting receptor populations or signaling pathways responsible for DOR-
mediated analgesic and antidepressant-like effects without activating receptors that mediated 







 The use of opium, extracted from the poppy plant Papaver somniferum, predates 
recorded history. It was used for the treatment of pain and diarrhea, as well as for its euphoric 
effects. In the early 19th century, the opiates primarily responsible for these effects, morphine and 
codeine, were isolated. Over the next century and a half, additional opioids were discovered and 
synthesized including heroin, meperidine and methadone. By the 1970s it had become apparent 
that the effects of opioids could best be explained by the presence of multiple opioid receptor 
types, which in turn suggested that these receptors were the target of endogenous 
neurotransmitters (Goldstein et al. 1971; Kuhar et al. 1973). Three types of opioid receptors—mu 
(MOR), delta (DOR), and kappa (KOR)—were identified and found to be activated by several 
endogenous opioid peptides (Martin et al. 1976; Lord et al. 1977). β-endorphin is derived from 
prepro-opiomelanocortin (POMC) and activates MOR and DOR with equal potency. Leu- and 
met-enkephalin are cleaved from preproenkephalin and bind and activate DOR with 
approximately 10-fold selectivity over MOR. Dynorphin A and B are derived from 
preprodynorphin and potently activate KOR with minor activity at MOR (Corbett et al. 1993). 
 The three opioid receptor types are each associated with pronounced and distinct 
behavioral effects. Activation of MOR produces robust analgesia, but also causes adverse effects 
including constipation, respiratory depression, and itch. In addition, MOR agonists have a strong 
reinforcing effects that can lead to dependence and addiction. Although KOR agonists also 
produce analgesia, they induce feelings of dysphoria and hallucinations, limiting widespread 
clinical use. Activation of DOR produces weak analgesia in models of acute pain—though these 
effects are more robust in models of inflammatory and neuropathic pain —as well as 
antidepressant-like, anxiolytic, stimulant, and anti-Parkinsonian effects. Some DOR agonists also 
produce convulsions which has limited their clinical development (for review see Chu Sin Chung 
and Kieffer 2013; Al-Hasani and Bruchas, 2011). It has been proposed that multiple subtypes 
(i.e. DOR1, DOR2) of each opioid receptor exist and these subtypes may mediated only certain 
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behavioral effects of the receptor, but this hypothesis remains controversial (for review, see 
Dietis et al. 2011). 
 In the 1980s, opioid receptors were thought to belong to the family of G protein coupled 
receptors (GPCRs) and couple to inhibitory Gi/o proteins due their sensitivity to pertussis toxin 
and their ability to activate inwardly rectifying potassium channels (Burns et al. 1983; North et 
al. 1987). This hypothesis was later confirmed in the early 1990s with the cloning of each 
receptor type (Evans et al. 1992; Chen et al. 1993; Minami et al. 1993). All GPCRs transmit 
extracellular stimuli into intracellular signaling through coupling to heterotrimeric G proteins, 
each comprised of an α and βγ subunit (Figure 1.1; Gilman, 1987). In an inactive state, the 
heterotrimeric G protein exists as a single complex with Gα bound to GDP. Activation of a 
receptor by a ligand produces a conformational change in the Gα subunit, causing it to exchange 
GDP for GTP and dissociate from the βγ subunit. The α and βγ subunits go on to participate in 
various signaling cascades depending on the G protein subtype. The subunits remain active until 
the GTP bound to Gα is hydrolyzed to GDP, increasing the affinity of Gα for Gβγ and allowing 
the heterotrimer to reform. Gα possesses intrinsic GTPase activity that hydrolyzes GTP at a slow 
rate. This activity is greatly accelerated by regulator of G protein signaling (RGS) proteins. 
Following agonist activation, GPCRs are typically phosphorylated by G protein-coupled receptor 
kinases (GRKs) which facilitates arrestin binding to the receptor. Once bound to the 
phosphorylated GPCR, arrestin can mediate receptor internalization and recruit other signaling 
proteins to promote G protein-independent signaling pathways (Galandrin et al. 2007; Reiter et 
al. 2012).  
 Agonists that act at the same orthosteric site on a GPCR can stabilize distinct active 
conformations that preferentially signal through G protein or arrestin, a phenomenon known as 
functional selectivity or biased agonism (Kenakin 2003). These distinct G protein- and arrestin-
dependent pathways may produce different behavioral effects. For example, targeted knockdown 
of specific G protein subunits using antisense nucleotides inhibited DOR-mediated 
antinociception in mice, suggesting that this effect is produced by a G protein-dependent 
signaling pathway (Standifer et al. 1996; Sánchez-Blázquez and Gárzon 1998). In addition, DOR 
agonists have been shown to differentially recruit arrestin isoforms and tolerance to the 
antinociceptive effects of an agonist depends on the arrestin isoform recruited (Pradhan et al. 
2016).  Loss of regulator of G protein signaling 4 (RGS4) potentiated the antidepressant-like 
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effects of the DOR agonist SNC80 suggesting that this behavior may be generated through G 
protein signaling (Stratinaki et al. 2013). The behavioral consequences of biased agonism in the 
DOR system are only beginning to be explored, and it remains unclear whether other behavioral 
effects of DOR, such as convulsive effects, are mediated by G protein or arrestin. 
 DOR represents a promising therapeutic target due its combination of beneficial effects 
and the prevalence of people with comorbid pain and depression. Nevertheless, the development 
of DOR drugs without convulsive effects is still needed. Determining the mechanisms and 
intracellular signaling pathways that give rise to DOR-mediated behaviors, and DOR-mediated 
convulsions in particular, is critical for the development of such drugs. Therefore, the current 
project explored the role of distinct signaling pathways and agonist efficacy in eliciting DOR-
mediated behavioral outcomes using a variety of transgenic mouse models and behavioral 
pharmacology techniques.  
 
Chronic Pain and Depression 
Chronic pain and depression are widespread and debilitating diseases that, for many 
people, cannot be adequately addressed with current treatment options. Major depressive 
disorder (MDD) is a psychiatric disease in which those affected experience a depressed mood 
(i.e. feelings of sadness, emptiness, or hopelessness) and/or a loss of interest or pleasure in 
everyday activities. The recently released fifth edition of the Diagnostic and Statistical Manual of 
Mental Disorders defines a person as having a major depressive episode when they exhibit one 
of the former symptoms and at least four of the following within a two week period: 1) 
significant changes in weight or 2) sleeping pattern, 3) agitation, 4) fatigue, 5) feelings of 
worthlessness or excessive guilt, 6) diminished concentration, and/or 7) recurring thoughts of 
death or suicide (APA, 2013). In addition, MDD often presents with comorbidities such as 
chronic pain and anxiety disorders.  
Major depression is a pervasive disease, affecting around 350 million (1 in 20) people 
worldwide (WHO, 2012). It is the top cause of disability in terms of total years lost to to the 
illness and is the leading cause of disease burden in women regardless of income (WHO, 2008). 
Furthermore, this disease appears to have lasting, cross-generational effects as evidence points to 
a mother with depression being a risk factor for poor growth and development in children 
(Rahman et al. 2008). However, the gravest concern with a depressed patient is an increased risk 
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of suicide. MDD is responsible for approximately half of all suicides in the United States with 
15% of people with depression eventually committing suicide (Loosen and Shelton 2008). 
The etiology of depression is unclear. Until recently, the prevailing hypothesis posited 
that depression was caused by deficiencies in the neurotransmission of monoamines, specifically 
serotonin and norepinephrine. Therefore, current treatments for depression have focused on 
enhancing monoaminergic signaling. Although there are currently several methods for treating 
major depression, no single pharmacological treatment has been widely effective or without 
serious shortcomings. The selective serotonin reuptake inhibitors (SSRIs) are the first line 
therapy and most commonly used drug class for the treatment of major depression. SSRIs act by 
blocking the reuptake of serotonin into presynaptic nerve terminals thereby increasing 
neurotransmitter signaling. Although this action of SSRIs occurs immediately, it can take up to 
six weeks for an SSRI to reach full effect in depressed patients (Trivedi et al. 2006a). This 
finding suggests that monoamine deficiency alone is not sufficient to produce depression or that 
enhancement of monoaminergic signaling is not solely necessary for producing therapeutic 
effects. In further support of this hypothesis, 70% of patients do not achieve remission with an 
SSRI alone (Trivedi et al. 2006a). Augmenting SSRI treatment with a second antidepressant can 
be helpful although only a third of patients who do not respond to SSRI monotherapy achieve 
remission with combination therapy (Trivedi et al. 2006b). Furthermore, SSRI treatment can lead 
to serious complications including tinnitus, insomnia, akathisia, and sexual dysfunction.  
The tricyclic antidepressants (TCAs) are an alternative treatment for major depression 
and were the primary therapy prior to the development of SSRIs. TCAs act through a variety of 
mechanisms, however the majority block serotonin and/or norepinephrine reuptake. Like SSRIs, 
TCAs can also take several weeks to reach their full effect and effectively treat a small 
percentage of patients. In the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) clinical trial, about 20% of patients not adequately treated with SSRI mono- or 
combination therapy achieve remission with a TCA (Fava et al. 2006). TCAs can also have 
effects on the cardiovascular system including changes in heart rate or rhythm and orthostatic 
hypotension. Furthermore, the therapeutic index of TCAs is small and overdoses can be lethal 
making administration of these drugs to suicidal patients concerning. Other traditional 
medications used for the treatment of depression include serotonin receptor agonists, serotonin 
and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs). 
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An alternative to pharmacotherapy, and arguably the most effective treatment for major 
depression currently available, is electroconvulsive therapy (ECT; Polyakova et al. 2015). ECT 
works by using an electric current to induce a generalized seizure in the central nervous system 
of the patient. The mechanism by which this seizure alleviates depressive symptoms is currently 
unknown, although there is evidence that it involves modulation of the opioid system (Emrich et 
al. 1979; Inturrisi et al. 1982). The primary side effects associated with ECT are confusion and 
memory loss. Although rare, this memory loss is potentially permanent. Other problems 
surrounding ECT include insufficient patient understanding and public disapproval of its use 
(Eisendrath and Lichtmacher 2014). 
Although the majority of antidepressant therapies function via augmentation of 
aminergic neurotransmission, the monoamine deficiency hypothesis of depression is likely 
overly simplistic as several alternative targets including GABA, glutamate, adenosine, stress 
hormones, and opioids have been proposed to be involved in mediating depressive symptoms. 
Changes in opioid signaling have already been observed with currently used treatments for 
depression, such as ECT, and the atypical antidepressant tianeptine, which was recently shown to 
be an agonist at both MOR and DOR opioid receptors, albeit at large concentrations (Gassaway 
et al. 2014). Case studies have also reported that the opioid ligand buprenorphine has 
antidepressant actions in patients with refractory depression, potentially through inhibition of 
kappa opioid receptors (for review, see Stanciu et al. 2017). Despite these findings, the use of 
opioids for the treatment of depression is rarely discussed. 
Depression and chronic pain are often comorbid. Among people suffering from chronic 
pain, it is estimated that 30-54% of them also suffer from MDD (Gieseke et al. 2005). 
Conversely, in a study of 150 MDD patients, 76% of them exhibited multiple pain symptoms 
(Corruble and Guelfi, 2000). In addition, this study found that pain complaints correlated with 
the severity of depression symptoms. Pain can be difficult to characterize and can be due to a 
number of factors but is commonly defined as an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage (IASP, 2014). Chronic pain, defined as pain 
persisting for at least three months, is a condition that affects roughly 100 million Americans 
(Henschke et al. 2015). The economic burden of chronic pain is enormous, costing the United 
States over $500 billion annually in healthcare costs and lost productivity, a total greater than the 
cost of heart disease, diabetes, and cancer combined (Gaskin and Richard 2012).  
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MOR agonists, such as hydrocodone and fentanyl, are widely used for the treatment of 
chronic pain. MOR agonists act in a number of brain regions to stimulate descending inhibitory 
pathways and blunt nociceptive transmission from the periphery to the CNS. Although these 
drugs have demonstrated efficacy for some types of pain, including postoperative and 
breakthrough cancer pain, MOR agonists are significantly less effective at treating other types of 
pain, such as neuropathic and inflammatory pain. Switching between different MOR agonists 
and/or routes of administration, a strategy known as opioid rotation, may maintain analgesia 
while limiting adverse effects though there is a lack of strong evidence in support of this strategy 
(Nalamachu 2012). Many physicians still utilize opioid rotation, however finding equi-analgesic 
doses can be difficult and there are no evidence-based guidelines regarding opioid choice (Smith 
and Peppin 2014).  
The GABA analogues gabapentin and pregabalin are commonly used for the treatment 
of neuropathic pain. It is unclear how these drugs function, but it has been proposed to be due to 
inhibition of voltage-gated sodium channels through interaction with the α2δ subunit. While 
gabapentin and pregabalin are typically well tolerated, they are not particularly efficacious and 
produce a 50% reduction of pain levels in only 20-40% of patients (Gilron and Flatters 2006; et 
al. 2014). TCAs, amytriptyline in particular, are also used to treat neuropathic man. Like the 
GABA analogues, TCAs are effective in only 20-30% of patients (Kremer et al. 2016). In 
addition, TCAs require prolonged treatment to achieve efficacy and are associated with serious 
adverse effects as previously discussed. Given the inadequacy of available treatments, there is a 
demonstrable need for alternative therapies for major depression and chronic pain. 
 
Antidepressant-like Effects and DOR Activation  
 
Evidence from Preclinical Models 
In 1975, peptides with opiate-like properties were observed in the aqueous extracts of pig 
brain and human cerebrospinal fluid (Hughes 1975a; Terenius and Wahlström 1975). These 
compounds were quickly identified as the pentapeptides leu- (Tyr-Gly-Gly-Phe-Leu) and met-
enkephalin (Tyr-Gly-Gly-Phe-Met; Hughes et al. 1975b). The following year, Plotnikoff et al. 
(1976) showed that met-enkephalin potentiated increases in motor activity produced by racemic 
dihydroxyphenylalanine (DOPA). Because the tricyclic antidepressants were also effective in 
this assay, it was used as an early screening technique for antidepressant drugs (Everett, 1966). 
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The antidepressant-like effects of opioids were further supported when enkephalins and 
endorphins were shown to decrease immobility in the forced swim test and the learned 
helplessness paradigm, again demonstrating effects similar to clinically used antidepressants 
(Kastin et al. 1978; Tejedor-Real et al. 1995). Later, numerous experiments showed that 
preventing the breakdown of endogenous opioid peptides using enkephalinase inhibitors 
produced antidepressant-like effects. Tejedor-Real et al. (1993) demonstrated that RB38A, a 
mixed enkephalinase inhibitor, and RB38B, a selective endopeptidase EC 3.4.24.11 inhibitor, 
reduced escape failures in the learned helplessness paradigm, and that these effects were blocked 
by the nonselective opioid receptor antagonist naloxone, suggesting an opioid receptor-mediated 
effect. In the mouse forced swim test, the enkephalinase inhibitor BL-2401 produced naloxone-
reversible antidepressant-like effects, again indicating an opioid receptor-mediated effect (Kita, 
et al. 1997). 
However, these experiments did not necessarily demonstrate a role for the DOR in 
mediating these behaviors. Inhibition of the effects of RB101, a mixed enkephalinase inhibitor, 
and the DOR selective peptide agonist BUBU (Tyr-D.Ser-(O-tert-butyl)-Gly-Phe-Leu-Thr(O-
Tet-butyl-OH)), in the learned helplessness paradigm by the DOR selective antagonist 
naltrindole (NTI), suggested that the antidepressant-like effects of these drugs were DOR-
mediated in mice (Baamonde et al. 1992) and rats (Tejedor-Real et al. 1998). RB101 was later 
shown to consistently produce DOR-mediated antidepressant-like effects in the rat forced swim 
test (Jutkiewicz et al. 2006). Recently, opiorphin, an endogenously expressed inhibitor of human 
neutral endopeptidase and aminopeptidase-N, was found to induce antidepressant-like effects in 
the rat forced swim test (Javelot et al. 2010). These effects were blocked by NTI as well as the 
MOR selective antagonist β-funaltrexamine (β-FNA), indicating a role for both DORs and 
MORs (Javelot et al. 2010; Yang et al. 2011). Although these studies demonstrate that 
stimulation of the DOR produces antidepressant-like effects in animal models, they do not 
indicate the role of the endogenous DOR system or endogenous opioids in regulating mood 
states. To this end, König and colleagues (1996) found that mice lacking preproenkephalin 
displayed anxiety-related behaviors and the males were also hyperaggressive. Later, Filliol et al. 
(2000) demonstrated a role for endogenous delta opioid tone in the regulation of mood states by 




The development of nonpeptidic DOR selective agonists greatly aided the investigation 
of DOR-mediated antidepressant-like effects by allowing for the study of centrally mediated 
behaviors using peripherally administered compounds. The nonpeptidic DOR selective agonists 
(+)BW373U86 ((±)-4-((α-R*)-α-(2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-
hydroxybenzyl)-N,N-diethylbenzamide), SNC80 ((+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-
dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide), and TAN-67 ((-)-2-methyl-
4aα-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aα-octahydorquinolino[2,3,3g]isoquiniline 
dihydrobromide) all demonstrated antidepressant-like effects in the rat forced swim test (Table 
1.1; Broom et al. 2002a; Nagase et al. 2002). The effects of (+)BW373U86 and SNC80 were 
shown to be NTI-reversible indicating a DOR-mediated effect (Broom et al. 2002a). 
Additionally, SNC80 has been found to elicit other antidepressant-like effects, including 
improving the emotionality score in olfactory bulbectomized rats (Saitoh et al. 2008) and 
reversing pain depressed responding of intracranial self-stimulation in rats (Negus et al. 2012). 
Furthermore, SNC80 is not self-administered by monkeys (Negus et al. 1998), does not facilitate 
intracranial self-stimulation (Do Carmo et al. 2009), and does not promote dopamine efflux in 
the nucleus accumbens (Longoni et al. 1998), suggesting a low abuse potential. Unlike typical 
antidepressants, which require multiple administrations to generate an effect in many animal 
models of depression, these DOR agonists were effective after a single, acute dose, suggesting a 
faster onset of action. Although tolerance develops to some of the effects of DOR agonists after a 
single dose, DOR agonists continue to produce antidepressant-like effects after repeated 
administration (Jutkiewicz et al. 2005a; Saitoh et al. 2008; Nozaki et al. 2014).  
Due to the effectiveness of ECT in treating depression in humans, it was hypothesized 
that DOR agonist-induced convulsions were required for their antidepressant-like effects, similar 
to that produced by other convulsive agents that had been used clinically prior to the 
development of ECT, such as metrazol or insulin-induced seizure. DOR agonist-induced 
convulsions consist of brief, non-lethal, generalized seizure activity, are NTI-sensitive, and 
absent in DOR knockout mice (Comer et al. 1993; Broom et al. 2002b). Broom et al. (2002b) 
showed that pretreatment with the short acting benzodiazepine midazolam blocked 
(+)BW373U86-induced convulsions without affecting (+)BW373U86-induced antidepressant-
like effects. By slowing the rate at which SNC80 was administered, Jutkiewicz et al. (2005b) 
eliminated the convulsive effects of SNC80 while maintaining its antidepressant-like effects. 
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Additionally, they were able to elicit convulsions without observable antidepressant-like effects 
in the forced swim test in rats at a dose of 1 mg/kg SNC80 via rapid (20 sec) intravenous 
infusions. Moreover, tolerance to the convulsive effects of DOR agonists develops after a single 
administration, whereas the antidepressant-like effects remain after chronic administration. 
Recently, it was shown that loss of DOR expression in GABAergic forebrain neurons in mice 
eliminated SNC80-induced convulsions and EEG disturbances (Chu Sin Chung et al. 2015). 
Taken together, these data suggest that it is possible to observe antidepressant-like effects of 
DOR agonists without generating convulsions.  
In further support of this hypothesis, nonpeptidic DOR agonists that produce 
antidepressant-like effects without generating convulsions, including ADL5859 and KNT-127, 
have been developed. ADL5859 (N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-
yl) benzamide; Table 1.1) significantly reduced immobility and increased swimming when 
administered at 3 mg/kg orally in a rat forced swim test (Le Bourdonnec et al. 2008). These 
antidepressant-like effects were not accompanied by any convulsions, hyperlocomotion, or 
stereotypy in rats or mice at doses up to 1 g/kg. In addition, no EEG disturbances were observed 
in rats at doses up to 30 mg/kg i.v. (Le Bourdonnec et al. 2008) or in mice at doses up to 300 
mg/kg p.o. (Chu Sin Chung et al. 2015). ADL5859 passed phase I clinical trials and was 
evaluated in human clinical trials for the treatment of rheumatoid arthritis and neuropathic pain 
but was not found effective (Spahn and Stein 2017). To this point, studies evaluating ADL5859 
as a treatment for depression in humans have not been conducted.  
KNT-127 (1,2,3,4,4a,5,12,12a-octahydro-2-methyl-4aβ,1β-([1,2]benzenomethano)-2,6-
diazanaphthacene-12aβ,17-diol; Table 1.1) has been extensively investigated in animal models of 
depression and anxiety. In the mouse forced swim test, KNT-127 significantly decreased 
immobility and increased swimming behavior without affecting overall locomotor activity or 
eliciting convulsions (Saitoh et al. 2011). These antidepressant-like effects of KNT-127 were 
reversed by NTI as well as the putative DOR2 antagonist naltriben. Daily injections of 5 mg/kg 
KNT-127 did not affect the ability of acute administration of 3 mg/kg KNT-127 to reduce 
immobility in the mouse forced swim test suggesting that chronic administration of KNT-127 
does not induce tolerance to its antidepressant-like effects (Nozaki et al. 2014). Furthermore, 
daily administration of KNT-127 significantly decreased hyperemotionality scores in olfactory-




Possible Mechanisms of Action of DOR-Mediated Antidepressant-like Effects 
Although monoamines, namely dopamine, norepinephrine and serotonin, play a well-
established role in regulating emotion and cognition (Robbins and Arnsten 2009), the etiology of 
depression goes beyond deficiencies in the levels of these neurotransmitters in the brain. There 
are two primary problems with the monoamine deficiency hypothesis of depression. First, 
although clinically used antidepressants typically take weeks to achieve a therapeutic effect, they 
block reuptake and/or metabolism of monoamines within hours or days of first use. Second, loss 
of serotonin or norepinephrine does not readily cause depression in healthy controls suggesting 
that monoamine deficiency is not sufficient to produce depression. Therefore, alternatives to the 
monoamine hypothesis of depression have been put forward.  
One such hypothesis proposes that depression is caused by dysfunction of glutamatergic 
neurotransmission. Excess glutamate leads to neurotoxicity and this loss of neurons is thought to 
promote a depressive phenotype, even though many studies have shown that inhibition of 
neurogenesis does not lead to a depressive phenotype (for review see Petrik et al. 2012). Many 
clinical studies have shown elevated levels of glutamate in the plasma, CSF, and brain tissue of 
depressed patients that are reduced after antidepressant treatment (for review see Sanacora et al. 
2012). In addition, low doses of the noncompetitive NMDA receptor antagonist ketamine have 
been shown to elicit rapid antidepressant-like effects in human patients (Monteggia and Zarate 
2015) and animal models (Browne and Lucki 2012). These effects last for up to two weeks after 
a single dose of ketamine suggesting a synaptic plasticity-mediated mechanism. 
The interactions between the delta opioid and glutamatergic systems are not well 
characterized and differ across brain regions. SNC80 has been found to increase glutamate 
release in rat striatum (Bosse et al. 2014). KNT-127 increased glutamate release within the 
striatum, nucleus accumbens, and medial prefrontal cortex of male Sprague-Dawley rats 
(Tanahashi et al. 2012). The peptidic delta agonist DPDPE enhanced the glutamate content of 
intrastriatal dialysate (Billet et al. 2004), but also inhibited glutamate release in the rat anterior 
cingulate cortex (Tanaka and North 1994) and in the amygdala of morphine treated rats (Bie et 
al. 2009). The peptidomimetic DOR agonist UFP-512 decreased glutamate release in the rat 
substantia nigra (Mabrouk et al. 2009). Further research is needed to characterize the role of 
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glutamate and glutamate circuitry in depression and in eliciting DOR-mediated antidepressant-
like effects. 
Another putative mechanism for the actions of antidepressant drugs is through 
upregulation of brain derived neurotrophic factor (BDNF). BDNF is a member of the 
neurotrophin family of growth factors and promotes the growth, survival, and differentiation of 
neurons. Many studies have shown that stress decreases BDNF expression and promotes cell 
death in brain regions that regulate mood (Duman 2003; Lee and Kim 2010). Serum levels of 
BDNF in depressed patients are significantly lower compared to healthy controls (Bocchio-
Chiavetto et al. 2010). In postmortem studies, BDNF expression was decreased in the 
hippocampus and prefrontral cortex of depressed patients and suicide victims (Dwivedi et al. 
2003; Karege et al. 2005). Furthermore, antidepressant treatment has been shown to increase 
BDNF expression in preclinical and clinical studies (Duman 2003; Lee and Kim 2010). 
There are few reports examining the effects of DOR agonists on BDNF. DPDPE 
increased BDNF mRNA expression in the rat frontal cortex (Torregrossa et al. 2006) while 
(+)BW373U86 increased BDNF mRNA expression in the hippocampus, amygdala, and frontal 
cortex (Torregrossa et al. 2004). For both drugs, these changes were NTI-sensitive and occurred 
at doses that also produced antidepressant-like effects in the forced swim test. Interestingly, 
upregulation of BDNF in response to DOR agonists was observed before increases could be 
observed with traditional antidepressants, suggesting a faster onset of action. Elevated levels of 
BDNF mRNA in the frontal cortex persisted after 8 days of daily (+)BW373U86 injections but 
returned to basal levels after 21 days of treatment. However, it is unclear whether or not BDNF 
protein levels were also changed (Torregrossa et al. 2005). UFP-512 attenuated hypoxia-induced 
decreases in BDNF expression in mouse cortex exposed to hypoxic (10% O2) conditions for 3 or 
10 days (Tian et al. 2013). The nonpeptidic DOR agonist AZD2327 significantly increased 
BDNF expression in the rat hippocampus but not in the frontal cortex and plasma BDNF levels 
remained unchanged (Richards et al. 2016). AZD2327 also failed to alter plasma BDNF levels in 
human patients, albeit in a small, underpowered cohort (Richards et al. 2016).  Taken together, 
these data suggest that BDNF expression may correlate with the antidepressant actions of DOR 





Pain Relieving Effects and DOR Activation 
 
Evidence from Preclinical Models 
Following the isolation of leu- and met-enkephalin, these pentapeptides were tested for 
analgesic properties. Both peptides produce antinociception in the hot plate and tail flick tests in 
rats when given intraventricularly (Frederickson 1977). However, these effects were produced 
with low potency and only for a short duration due to rapid degradation. Single peptide 
substitutions, such as replacing the first glycine of met-enkephalin with D-alanine, greatly 
increased the potency and duration of antinociceptive action. Naloxone antagonized enkephalin-
induced antinociception with potency comparable to morphine, suggesting that these effects are 
mediated by MOR (Yaksh et al. 1978).  
Evidence for DOR-mediated antinociception was first found with intrathecal 
administration of the peptide DADLE (Tyr-D-Ala-Gly-Phe-D-Leu). Naloxone antagonized 
DADLE-induced antinociception in the rat hot plate test with significantly lower potency 
compared to morphine-induced antinociception (Tung and Yaksh, 1982). In addition, this report 
also found that DADLE produced antinociception with similar potency in naïve and morphine 
tolerant rats. Taken together, these data suggest that DADLE-induced antinociception is 
mediated by a receptor other than MOR. Jensen and Yaksh (1986) found that injecting DADLE 
directly into the periaqueductal gray (PAG) or the medullary reticular formation was sufficient to 
produce antinociception in the tail flick and acetic acid-induced stretching tests. DPDPE (Tyr-D-
Pen-Gly-Phe-D-Pen), a cyclized peptide with greater selectivity for DOR than MOR, produced 
antinociception in models of acute pain including the tail flick and paw pressure tests (Rodriguez 
et al. 1986). This report also showed that the DOR selective antagonist ICI 174,864 blocked 
DPDPE-mediated, but not morphine-mediated, antinociception, indicating a DOR-mediated 
effect. In a formalin-induced inflammation model in rats, DPDPE reduced nocifensive paw 
licking suggesting DOR agonists could be effective at treating inflammatory pain (Calgnetti et al. 
1988). DPDPE also alleviated cold water allodynia in rats with a crushed sciatic nerve, a model 
of neuropathic pain (Mika et al. 2001). This effect of DPDPE was blocked by pretreatment with 
the putative DOR1 antagonist 7-benzylidenenaltrexone (BNTX), indicating a DOR-mediated 
effect. 
As with antidepressant-like effects, evaluation of DOR-mediated analgesia benefited 
from the development of small molecule DOR selective agonists and antagonists. Peripheral 
13 
 
administration of SNC80 or BW373U86 did not produce DOR-mediated antinociception in 
models of acute thermal nociception such as the hot plate, tail flick, and warm water tail 
withdrawal assays in rodents (Wild et al. 1993; Bilsky et al. 1995; Gallantine and Meert 2005) or 
in monkeys (Negus et al. 1998). However, these drugs did produce dose-dependent DOR-
mediated antinociception in other pain models such as the acetic acid-induced stretch assay 
(Wild et al. 1993; Broom et al. 2002c; Gallantine and Meert 2005).  
SNC80 has demonstrated efficacy in several models of continuous inflammatory or 
neuropathic pain. SNC80 blocked capsaicin-induced thermal hyperalgesia in rhesus monkeys in 
a NTI-sensitive manner (Brandt et al. 2001). In addition, thermal hyperalgesia in rats produced 
by complete Freund’s adjuvant (CFA) was alleviated by SNC80 (Fraser et al. 2000). SNC80 also 
reduced nocifensive behavior induced by formalin and tactile allodynia following sciatic nerve 
injury in NTI reversible manners (Obara et al. 2009). In mice, SNC80 reversed mechanical 
allodynia and thermal hyperalgesia produced by CFA in wild-type but not DOR knockout 
animals (Gavériaux-Ruff et al. 2008; Nozaki et al. 2012). Furthermore, Gavériaux-Ruff et al. 
(2008) found that DOR knockout mice showed enhanced allodynic and hyperalgesic responses to 
CFA, suggesting a role for endogenous DOR tone in suppressing the response to inflammatory 
pain.  
These studies demonstrate that a single dose of a DOR agonist is effective at treating pain 
symptoms. However, the effects of a drug after repeated dosing is also critical to its clinical 
utility. Unfortunately, acute tolerance develops to the antinociceptive effects of some DOR 
agonists. Mice receiving repeated intercerebroventricular injections of DPDPE for 2 or 4 days 
displayed significant tolerance to the antinociceptive effects of DPDPE in the tail flick assay 
(Zhao and Bhargava 1997). A 24 hr pretreatment of SNC80 significantly decreased the 
antinociceptive effects of a second dose of SNC80 in the acetic acid-induced stretch assay in 
mice (Hong et al. 1998) or the lactic acid-induced stretch assay in rats (Negus et al. 2012). A 
single injection of SNC80 produced acute tolerance to the antihyperalgesic effects of a second 
dose of SNC80 given 4 or 12 hrs after the initial dose (Pradhan et al. 2010; Pradhan et al. 2016). 
Interestingly, arrestin2 knockout mice did not show tolerance to SNC80, suggesting arrestins 
may play a role in DOR desensitization (Pradhan et al. 2016). Waiting 24 hrs to give the second 
dose allowed SNC80 to produce a full response in wild-type mice, however the antihyperalgesic 
effects were completely lost after 5 daily injections of SNC80 (Pradhan et al. 2010).  
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It is possible that the antinociceptive effects of DOR are dependent on its convulsive 
effects, however this does not appear to be the case. BU48 (N-Cyclopropylmethyl-[7α,8α,2′,3′]-
cyclohexano-1′[S]-hydroxy-6,14-endo-ethenotetrahydronororipavine; Table 1.1), a 
buprenorphine analog that acts as a partial agonist at DOR and KOR, produces DOR-mediated 
convulsions in mice without producing DOR-mediated antinociception (Broom et al. 2000). This 
finding suggests that DOR-mediated convulsions are not sufficient to produce antinociception. 
Furthermore, other DOR agonists have been shown to provide antinociception without producing 
convulsions.  
ARM390 (N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide; Table 1.1) has 
been shown to produce antihyperalgesia with reduced tolerance relative to SNC80. In mice 
treated with CFA, ARM390 reversed thermal antihyperalgesia acutely and in mice pretreated 
with ARM390 12 or 24 hrs prior to a second dose (Pradhan et al. 2010). However, after 5 days of 
daily treatment ARM390 failed to inhibit thermal or mechanical hyperalgesia. ARM390 had 
similar effects on nitroglycerin-induced hyperalgesia after both acute and repeated dosing 
(Pradhan et al. 2014). There are no reports of ARM390 producing convulsions and it did not 
generate changes in EEG recordings at doses up to 60 mg/kg p.o. (Chu Sin Chung et al. 2015). 
JNJ-20788560 (9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid 
diethylamide; Table 1.1) is a DOR agonist of particular interest because it appears to produce 
antinociception with little development of tolerance. Acutely, 30 mg/kg p.o. JNJ-20788560 
inhibited CFA-induced thermal hyperalgesia in rats and acetylcholine bromide-induced 
stretching in mice (Codd et al. 2009). Tolerance to these effects did not develop after 5 days of 
daily treatment with JNJ-20788560. Pradhan et al. (2014) showed that JNJ-20788560 could 
reverse nitroglycerin-induced mechanical hyperalgesia in mice with no significant tolerance 
when given every other day for 10 days (Pradhan et al. 2014). There are no reports of JNJ-
20788560 producing convulsions. 
KNT-127 also displays a variety of antinociceptive effects. KNT-127 reduced acetic acid-
induced stretching as well as paw licking in the formalin test (Nagase et al. 2010; Saitoh et al. 
2011). These behaviors were blocked by pretreatment with NTI and naltriben demonstrating that 
the antinociceptive effects of KNT-127 are DOR-mediated. KNT-127 also reversed thermal and 
mechanical hyperalgesia in mice treated with CFA (Nozaki et al. 2014). This study also found 
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that daily treatment of KNT-127 for 5 days produced full tolerance to the antihyperalgesic effects 
of KNT-127 and cross-tolerance to the antihyperalgesic effects of SNC80. 
 
Possible Mechanisms of Action of DOR-Mediated Antinociceptive Effects  
The circuits governing DOR-mediated antinociception are well characterized. There are 
two primary neural circuits—the ascending and descending pathways—that regulate pain 
processing (Figure 1.2). Activation of the ascending pathway occurs when nociceptors, a class of 
afferent sensory neurons, relay noxious stimuli from the periphery to the spinal cord. There are 
two primary types of nociceptors that relay information to the spinal cord. Aδ fibers are 
myelinated, fast conducting neurons that release glutamate. Their signaling is thought to result in 
sharp, localized pain. C fibers are unmyelinated, slow conducting neurons whose signaling 
manifests as burning or throbbing pain that is poorly localized. They release neuropeptides such 
as substance P and calcitonin gene-related peptide. In the dorsal horn of the spinal cord, 
nociceptors synapse onto interneurons that signal to second order neurons that relay information 
up the spinal cord to the brain stem—specifically the PAG and raphe nuclei—and thalamus. 
Third order neurons receive signals in the thalamus and relay them to the somatosensory cortex 
of the brain where the noxious stimuli is interpreted as pain. The descending pathway involves 
efferent signaling from the PAG and raphe nuclei to the spinal cord that inhibits the ascending 
pathway. 
Multiple reports have located DORs in a variety of places along the ascending and 
descending pathways, namely in presynaptic terminals of C fiber neurons (Cheng et al. 1995; 
Mennicken et al. 2003), the cell bodies and dendrites of dorsal horn interneurons (Minami et al. 
1995; Cahill et al. 2001), and the PAG (Jenab et al. 1995; Kalyuzhny et al. 1996). Under basal 
conditions, a substantial portion of DORs are stored in intracellular vesicles that are trafficked to 
the plasma membrane in response to pain states such as chronic inflammation (Cahill et al. 2003; 
Gendron et al. 2006). DOR activation triggers a signaling cascade that inhibits voltage-dependent 
calcium channels (Acosta and López, 1999; Law et al. 2000; Pradhan et al. 2013). Because Ca2+ 
facilitates trafficking and fusion of synaptic vesicles to the plasma membrane, inhibition of Ca2+  
influx significantly reduces neurotransmitter release. This reduction of neurotransmitter release 
in turn prevents the relay of pain signals to subsequent neurons in the circuit and is theorized to 
be responsible for analgesia. DOR activation has also been linked to potassium efflux through 
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modulation of G protein-coupled inwardly rectifying potassium channels (GIRKs) which will 
hyperpolarize the neuron and further inhibit neurotransmitter release (Lüscher and Slesinger 
2010). Although there is strong evidence for DORs in the spinal cord mediating antinociception 
(Cahill et al. 2003; Gendron et al. 2006; Kouchek et al. 2013), DOR activation within the PAG 
appears to produce only mild antinociception (Ossipov et al. 1995; Morgan et al. 2009). 
 In summary, depression and pain are serious and intractable conditions that are not 
adequately treated with current therapies. DOR agonists have been shown to produce 
antidepressant-like effects and antinociception in a variety of animal models. The convulsive 
activity of several DOR agonists has heretofore limited their clinical utility, however the 
development of DOR agonists that do not produce convulsions should allow for more thorough 
testing in humans. Although some DOR agonists alter glutamatergic neurotransmission and 
others upregulate BDNF expression, consistent with modern hypotheses on the etiology of 
depression, the mechanism by which DOR-mediated antidepressant-like effects are generated is 
not known. In terms of DOR-mediated antinociception, the neuronal circuits governing these 
effects have been reasonably well characterized, however the intracellular signaling partners 
involved have not been elucidated. At the intracellular level, DOR-mediated behaviors may be 
generated via distinct intracellular signaling pathways. Determining the signal transduction 
mechanisms that give rise to DOR-mediated behaviors is critical for the development of DOR 
drugs with improved safety and clinical utility and future work should be devoted to elucidating 
these pathways.  
 
Experimental Objectives 
The experiments described in this thesis sought to further characterize the intracellular 
signaling pathways and mechanisms underlying DOR-mediated behaviors. Specifically, these 
studies focused on determining differences in the regulation of DOR-mediated convulsions 
relative to the potential therapeutic effects of DOR agonists. 
 
Aim 1: Characterize the role of RGS4 in the regulation of DOR-mediated behaviors 
The second Chapter of this thesis investigates how RGS4 regulates DOR-mediated 
behaviors by comparing the potency of SNC80 to produce antinociception, antihyperalgesia, 
antidepressant-like effects, and convulsions in wild-type and RGS4 knockout mice. Stratinaki et 
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al. (2013) previously showed that a single 5 mg/kg dose of SNC80 decreased immobility in the 
mouse forced swim test to a greater degree in RGS4 knockout mice compared to wild-type mice. 
This group of studies expands on those findings by evaluating other DOR-mediated behaviors 
using a wide range of doses. It was hypothesized that RGS4 negatively regulates all DOR-
mediated behaviors as evidenced by an increase in the potency of SNC80. Changes in SNC80 
potency were validated ex vivo by examining SNC80-induced phosphorylation of MAP kinase in 
striatum from RGS4 knockout mice. Potential changes in receptor density were measured using 
[3H]DPDPE saturation binding in mouse forebrain tissue. The relative contributions of DOR in 
the CNS and periphery to SNC80-induced behaviors were also evaluated using the peripherally-
limited antagonist N-methylnaltrexone. The results from this first study showed that DOR-
mediated antihyperalgesia and antidepressant-like effects in the forced swim test are regulated by 
RGS4, suggesting they are generated through a G protein signaling mechanism. 
 
Aim 2: Investigate the role of G protein- and arrestin-mediated signaling in DOR-mediated 
behaviors 
The third Chapter of this thesis investigates which G protein mediates these behaviors, as 
well as whether convulsions are produced via a G protein-dependent or –independent 
mechanism. It was hypothesized that Gαo mediates the antihyperalgesic and antidepressant-like 
effects of DOR while convulsions are mediated by arrestins. To evaluate the role of Gαo in DOR-
mediated behaviors, the potency of SNC80 to produce antihyperalgesia, antidepressant-like 
effects, and convulsions was assessed in Gαo RGS-insensitive heterozygous knock-in mice and 
Gαo heterozygous knockout mice. The effects of SNC80 were compared to the tricyclic 
antidepressant desipramine and the anti-migraine drug sumatriptan. DOR-mediated behaviors 
were also evaluated in arrestin2 and arrestin3 knockout mice. Potential changes in receptor 
density were measured using [3H]DPDPE saturation binding in mouse forebrain tissue. The 
study demonstrated that antidepressant-like effects and antihyperalgesia are likely mediated by 
Gαo protein signaling pathways but failed to find a signaling pathway that positively regulates 
DOR-mediated convulsions. 
 
Aim 3: Compare the efficacy requirements of DOR-mediated behaviors 
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The final data Chapter of this thesis evaluated the role of ligand efficacy as related to 
DOR-mediated convulsions. It was hypothesized that convulsions have the lowest efficacy 
requirement among the DOR-mediated behaviors tested, followed by antidepressant-like effects, 
with antihyperalgesia having the highest efficacy requirement. Efficacy requirements were 
assessed, in part, by comparing the behavioral effects of the DOR partial agonist BU48 and the 
DOR full agonist SNC80. Efficacy requirements were further evaluated by comparing the shifts 
in the SNC80 dose response curves for each of these behaviors in mice with decreased DOR 
number, such as DOR heterozygous knockout mice and following treatment with the DOR 
irreversible antagonist naltrindole-5’-isothiocyanate (5’-NTII). The potency of NTI to antagonize 
each of these SNC80-induced behaviors was also investigated. Overall, this study found that the 
observed behavioral effects of SNC80 display the following rank order of efficacy requirement: 
convulsions < antidepressant-like effects < antihyperalgesia. NTI antagonized these behaviors 
with distinct potencies, suggesting that discrete populations of DORs may mediate these 
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Figure 1.1. GPCR-mediated signaling mechanisms. In the inactive state, heterotrimeric G 
proteins exist as a single complex with Gα bound to GDP. Activation of a GPCR by a ligand 
produces a conformational change in the Gα subunit, causing it to exchange GDP for GTP and 
dissociate from the βγ subunit. The α and βγ subunits go on to activate various downstream 
effectors. The subunits remain active until the GTP bound to Gα is hydrolyzed to GDP, a process 
that is accelerated by RGS proteins. In addition to signaling through G proteins, GPCRs can also 
activate G protein-independent signaling via recruitment of arrestin proteins. Figure adapted 

























Figure 1.2. Ascending and descending pain pathways. Primary afferent nociceptors relay 
noxious stimuli from the periphery to the spinal cord. In the dorsal horn of the spinal cord, 
nociceptors synapse onto interneurons that signal to second order neurons that relay information 
up the spinal cord to the brain stem and thalamus. Third order neurons receive signals in the 
thalamus and relay them to the somatosensory cortex of the brain where the noxious stimuli is 
interpreted as pain. The descending pathway involves efferent signaling from the PAG and raphe 
nuclei to the spinal cord that inhibits the ascending pathway (yellow arrow). Figure adapted from 
Zhou and Verne 2014). 
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 Regulator of G protein signaling 4 (RGS4) is a member of the R4 subfamily of RGS 
proteins and interacts with Gαi/o proteins (Hollinger and Hepler 2002). Like other RGS proteins, 
RGS4 inhibits G protein signaling by binding Gα and accelerating Gα-mediated GTP hydrolysis. 
This acceleration of GTP hydrolysis shortens the lifetime of the active Gα-GTP complex and 
limits signal transduction to downstream effectors.  RGS4 is highly expressed in multiple brain 
regions including the cerebral cortex, amygdala, hippocampus and striatum (Nomoto et al. 1997) 
and negatively regulates signaling at multiple G protein-coupled receptor (GPCR) types 
including 5-HT1A (Gu et al. 2007), M3 muscarinic (Blazer et al. 2015), and delta (DOR) and mu 
(MOR) opioid receptors (Wang et al. 2009; Leontiadis et al. 2009).  
 Opioid receptors are class A GPCRs that couple to Gαi/o proteins. In rodents, activation of 
DOR induces antinociception, antihyperalgesia, and antidepressant-like effects without the 
constipation, respiratory depression, and abuse liability associated with mu opioid receptor 
agonists (for review see Chu Sin Chung and Kieffer 2013). Some DOR agonists also produce 
convulsions, hindering their development as therapeutics (Comer et al. 1993; Hong et al. 1998). 
Little is known about the signaling molecules and pathways involved in DOR-mediated 
behaviors and potential therapeutic effects. DOR is abundantly expressed in brain regions with 
high RGS4 expression (Lutz and Kieffer 2013). There are multiple, albeit somewhat discrepant, 
reports on the role of RGS4 in modulating opioid receptor function. In transfected HEK293 cells, 
RGS4 is recruited to the plasma membrane upon agonist-induced activation of DOR or MOPr 
where it associates with either receptor (Leontiadis et al. 2009). RGS4 also attenuated DOR- and 
MOPr-mediated phosphorylation of ERK in those cells. However, in a SH-SY5Y neuroblastoma 
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cell line endogenously expressing RGS4, DOR, and MOPr, siRNA-induced inhibition of RGS4 
potentiated ERK phosphorylation and inhibition of cAMP accumulation mediated by DOR, but 
not MOPr (Wang et al. 2009).  In vivo, a single dose of the DOR agonist SNC80 (5 mg/kg) in the 
mouse forced swim test (FST) decreased immobility to a greater degree in RGS4 knockout mice 
relative to wild-type mice (Stratinaki et al. 2013), suggesting that RGS4 may also regulate DOR 
signaling in vivo; however, its function is not clear based on this single dose experiment.  
The role of RGS proteins in modulating other DOR-mediated behaviors has not been fully 
elucidated. Determining the intracellular signaling pathways that give rise to DOR-mediated 
behaviors, and DOR-mediated convulsions in particular, is critical for the development of DOR 
drugs with improved safety and clinical utility. Therefore, to better understand the downstream 
signaling mechanisms, specifically the role of RGS4, contributing to DOR-mediated behaviors, 
we evaluated the effects of the DOR selective agonist SNC80 to induce antinociception, 
antihyperalgesia, antidepressant-like effects, and convulsions in wildtype and RGS4 knockout 
mice.  
 
Materials and Methods 
Subjects 
The Rgs4tm1Dgen/J mouse strain was obtained from The Jackson Laboratory (Bar 
Harbor, Maine, http://jaxmice.jax.org/strain/ 005833.html; Cifelli et al. 2008). Mice were 
backcrossed at least six generations into a C57BL/6 background and maintained in-house as 
heterozygote harem (1 male, 2 female) breeding groups. Wild-type littermates (+/+) were used as 
controls in all experiments involving C57RGS4 heterozygote (+/R4) and homozygote (R4/R4) 
knockout mice. For studies in which transgenic mice were not required, C57BL/6N mice (17-
30g) were obtained from Envigo (formerly Harlan, Indianapolis, IN). Mice were housed in 
groups of two to four animals per cage. Animals were used between 8 and 15 weeks of age at 
time of experiment and weighed 15-32 g. Mice had free access to standard lab chow and water 
and were maintained in a temperature- and humidity-controlled environment on a 12-h dark/light 
cycle with lights on at 7:00 AM. All animal use procedures complied with the Guide for the Care 
and Use of Laboratory Animals by the National Institutes of Health, and were approved by the 
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University of Michigan Institutional Committee on the Use and Care of Animals. Mice were 
tested only once, and all analyses are between-subject. 
 
Drugs 
All drugs were injected at a volume of 10 ml/kg unless otherwise noted. SNC80 ((+)-4-
[(R)--((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide) 
was dissolved in 1 M HCl and diluted in sterile water to a concentration of 3% HCl. Naltrindole 
5’ Naltrindole was dissolved in sterile water. N-methylnaltrexone (Sigma-Aldrich, St. Louis, 
MO) was dissolved in saline. The RGS4-selective RGS inhibitor CCG-203769 (2-ethyl-4-butyl-
1,2,4-thiadiazolidine-3,5-dione) was synthesized as previously described and dissolved in saline 
(Turner et al. 2012). Nitroglycerin (NTG) was provided by Dr. Adam Lauver (Department of 
Pharmacology, University of Michigan) and was diluted in saline. Glacial acetic acid 
(Mallinckrodt Specialty Chemicals, Paris, KY) was diluted in sterile water to a concentration of 
0.6% and given as a standard 0.4 ml similar to published methods (Broom et al. 2000, 2002b). 
All drugs were administered subcutaneously (sc) except for NTG and acetic acid which were 
given by intraperitoneal (ip) injection. 
 
Acetic Acid Stretch Assay 
The acetic acid stretch assay protocol was performed as previously described (Hong et al. 
1998; Broom et al. 2000; Broom et al. 2002). Male and female mice were injected with SNC80 
(1, 3.2, 10, 32 mg/kg), morphine (0.1, 1 mg/kg), or vehicle and immediately placed in separate 
cages (18 X 28 X 13 cm). 30 minutes following drug injection, 0.4 ml of 0.6% acetic acid was 
administered ip. Animals were observed for abdominal stretches for 30 min beginning 5 min 
after acetic acid administration. Abdominal stretches were characterized by contraction of the 
abdominal musculature and extension of the hind limbs. CCG-203769 (0.01, 0.1, 1 mg/kg) was 
administered 3 min after injection of acetic acid (2 min before observation of stretching). 
Naltrindole (3.2 mg/kg) was injected 30 min prior to, and naltrexone (3.2 mg/kg) and N-
methylnaltrexone (10 mg/kg) were injected 10 min prior to SNC80 administration.  
 
Tail Suspension Test 
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The procedure for the tail suspension test (TST) was adapted from Steru et al (1985). 
Male C57RGS4 mice were given SNC80 (0.32, 1, 3.2, 10 mg/kg) or vehicle. After 30 min, mice 
were suspended by their tail from a height of ~35cm using self-sticking tape and their behavior 
was recorded for 6 minutes using a Sony HDR-CX220 digital camcorder. In one experiment for 
comparison with the forced swim test (described below), mice were given SNC80 (1, 3.2, 10 
mg/kg) 60 min prior to the tail suspension test. Videos were analyzed by individuals blind to the 
experimental conditions, and the time (out of the total 6 min) which the animals spent immobile 
was quantified. Immobility was defined as the animal remaining motionless or making only 
minor, non-escape related movements. 
 
Forced Swim Test 
 The forced swim test was adapted from Porsolt et al (1977). Sixty min after SNC80 (0.1, 
0.32, 1, 3.2, 10, 32 mg/kg) or vehicle injection, each mouse was placed in a 4L beaker filled with 
15 cm of 25±1°C water and its behavior was recorded for 6 min using a Sony HDR-CX220 
digital camcorder. Videos were analyzed by individuals blind to the experimental conditions and 
the amount of time the animals spent immobile was quantified. Immobility was defined as the 
mouse not actively traveling through the water and making only movements necessary to stay 
afloat. The time the mouse spends immobile after the first 30 sec of the assay was recorded. 
 
Nitroglycerin-Induced Hyperalgesia 
The NTG-induced hyperalgesia assay was adapted from Bates et al (2010) using 
modifications described in Pradhan et al (2014).  Male C57BL6 or male and female C57RGS4 
mice were used to evaluate NTG-induced hyperalgesia. Hyperalgesia was assessed by immersing 
the tail (~5cm from the tip) in a 46°C water bath and determining the latency for the animal to 
withdraw its tail with a cut-off time of 60 sec. After determining baseline withdrawal latencies, 
10 mg/kg NTG (ip) was administered to each animal. Tail withdrawal latency was assessed again 
1 hr after NTG administration. At 90 min post-NTG, animals received an injection of SNC80 
(0.32, 1, 3.2, 10 mg/kg) or vehicle, and mice were observed continuously in individual cages for 
20 min to observe for convulsions (see section below). Tail withdrawal latencies were assessed 
again 30 min after SNC80 administration. Naltrindole (3.2 mg/kg) was injected 30 min prior to 
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SNC80 administration. Naltrexone (3.2 mg/kg) and N-methylnaltrexone (10 mg/kg) were 
injected 10 min prior to SNC80 administration (see Figure 2.4A). 
 
SNC80-Induced Convulsions  
Mice were observed continuously in individual cages for convulsions. NTG treatment 
had no effect on the frequency or nature of SNC80-induced convulsions (data not shown). 
Convulsions were comprised of a tonic phase characterized by sudden tensing of the musculature 
and extension of the forepaws followed by clonic contractions that extended the length of the 
body. Convulsions were followed by a period of catalepsy that lasted 2-5 min after which the 
animals were indistinguishable from untreated controls. Post-convulsion catalepsy was assessed 
by placing a horizontal rod under the forepaws of the mouse and a positive catalepsy score was 
assigned if the mouse did not remove its forepaws after 30 sec. 
 
DOR Saturation Binding and Signaling Assay 
RGS4 protein was identified in whole striatum of R4/R4 mice and wild-type littermates 
by Western blot as compared to purified RGS4 protein with a specific RGS4 antibody as 
previously described (Wang et al. 2009). -Tubulin was used as a loading control. For saturation 
binding assays, mice were decapitated and whole brain or striatum was removed and membranes 
were freshly prepared as previously described (Broom et al. 2002b).  Protein concentrations were 
determined with a BCA assay kit (Thermo Scientific, Rockford, IL). Specific binding of the 
DOR agonist [3H]DPDPE was determined as described using 10µM of the opioid antagonist 
naloxone to define non-specific binding as described (Broom et al. 2002b). Reactions were 
incubated for 60 min at 26ºC and stopped by rapid filtration through GF/C filter mats using a 
MLR-24 harvester (Brandel, Gaithersburg, MD). Bound [3H]DPDPE was determined by 
scintillation counting and Bmax and Kd values calculated using nonlinear regression analysis with 
GraphPad Prism version 6.02 (GraphPad, San Diego, CA).  
Whole striatal tissues from R4/R4 mice or wild-type littermates were incubated with or 
without 10 M SNC80 for 5 min at 37 °C. Samples were prepared and subjected to gel 
electrophoresis as previously described (Wang et al. 2009). The level of activation of the MAPK 
pathway was determined by Western blotting with anti-phospho-p44/42MAPK (Thr202/Tyr204) 
antibody or anti-p44/42 MAPK antibody (Cell Signaling Technology, Danvers, MA). Images 
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were acquired and quantified using an Odyssey FC imaging system (Li-COR Biosciences, 
Lincoln, NE). MAPK activity was calculated as the ratio of normalized arbitrary units (a.u.) of 
phosphorylated ERK1/2 over total ERK1/2 and presented as percent of vehicle-treated control. 
 
Data Analysis 
 Three-way ANOVA was performed using SPSS Statistics 22 (IBM, Armonk, NY). All 
other data analysis was performed using GraphPad Prism version 6.02 (GraphPad, San Diego, 
CA). Post hoc analysis was conducted using the Tukey’s post hoc test to correct for multiple 
comparisons. For all tests, level of significance ( was set to 0.05. ED50 values were calculated 
using GraphPad Prism version 6.02 by extrapolating the 50% maximum effect from the straight 
line analysis of the averaged treatment group data used to generate each dose effect function.  
 
Results 
Effects of RGS4 on DOR-Mediated Antinociception 
To determine whether RGS4 plays a role in DOR-mediated antinociception, the effects of 
the DOR agonist SNC80 were evaluated in RGS4 wild-type (+/+), heterozygous (+/R4), and 
homozygous (R4/R4) mutant mice in the acetic acid stretch assay (Figure 2.1A). Two-way 
ANOVA revealed a significant interaction (SNC80 dose [1-32 mg/kg only] X genotype, F(8,86) 
= 3.2, p =  0.0034), as well as significant main effects of SNC80 dose (F(4,86) = 15.4, p < 
0.0001) and genotype (F(2,86) = 25.07, p < 0.0001). Overall, the potency of SNC80 to reduce 
stretching was significantly increased in the RGS4 mutant mice as evidenced by an approximate 
6-fold leftward shift in the +/R4 dose effect curve and 27-fold leftward shift in the dose effect 
curve of the R4/R4 mice (ED50 values: +/+: 41 mg/kg; +/R4: 6.9 mg/kg; R4/R4: 1.5 mg/kg). 
 Because elimination or reduced levels of RGS4 enhanced SNC80-induced 
antinociception, we evaluated the effects of pharmacological inhibition of RGS4 with CCG-
203769 (Blazer et al. 2015) on SNC80-induced antinociception in C57BL6 wild-type mice 
(Figure 2.1B). Two-way ANOVA revealed a significant interaction (SNC80 dose X CCG-
203769 dose, F(3,42) = 3.9, p = 0.02) and significant main effects of SNC80 dose (F(1,42) = 
24.3, p < 0.0001) and CCG-203769 dose (F(3,42) = 6.9, p = 0.0007). Administration of either an 
ineffective SNC80 dose (3.2 mg/kg) or various doses of CCG-203769 alone did not alter 
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stretching behavior; however, CCG-203769 dose-dependently enhanced antinociception 
produced by 3.2 mg/kg SNC80, such that the combination of 3.2 mg/kg SNC80 with either 0.1 
mg/kg or 1 mg/kg CCG-203769 significantly reduced stretching.  
To assess the role of DOR in SNC80-induced antinociception in the acetic acid stretch 
assay, RGS4 knockout mice were pretreated with the DOR-selective antagonist naltrindole 
(Figure 2.1C). Three-way ANOVA revealed a significant main effect of SNC80 (F(1,63) = 38.7, 
p < 0.0001)  and a trend towards a significant SNC80 X genotype interaction (F(2,63) = 2.5, p = 
0.087). SNC80-induced reduction of stretching was completely blocked upon pretreatment with 
3.2 mg/kg naltrindole (SNC80 dose X naltrindole dose, F(1,63) = 52.2, p < 0.0001), indicating a 
DOR-mediated effect. This effect of naltrindole did not differ between RGS4 wild-type and 
mutant mice. 
To investigate whether the effects of SNC80 in the acetic acid stretch assay were 
peripherally- or centrally-mediated, C57BL6 wild-type mice were pretreated with the 
nonspecific opioid antagonist naltrexone or its peripherally-limited analog N-methylnaltrexone 
in the acetic acid stretch assay (Figure 2.1D). Administration of 32 mg/kg SNC80 significantly 
reduced stretching in vehicle-pretreated animals, but pretreatment with either 3.2 mg/kg 
naltrexone or 10 mg/kg N-methylnaltrexone significantly attenuated the SNC80-induced 
reduction in stretching (one-way ANOVA: F(3,20) = 14.6, p < 0.0001). 
To determine whether the role of RGS4 in opioid-induced antinociception was limited to 
DOR-mediated antinociception, the mu opioid receptor agonist actions of morphine were 
evaluated in RGS4 transgenic mice in the acetic acid stretch assay (Figure 2.1E). The main effect 
of morphine dose was significant (F(2,45) = 28.5, p < 0.0001) but there was no main effect of 
genotype and no morphine dose X genotype interaction.  Increasing doses of morphine produced 
similar decreases in stretching in RGS4 +/+, +/R4, and R4/R4 mice. In addition, pharmacological 
inhibition of RGS4 by CCG-203769 did not alter the effects of morphine in the acetic acid 
stretch assay (Figure 2.1F). Treatment of C57BL6 wild-type mice with 0.1 mg/kg morphine 
significantly reduced stretching relative to vehicle treated controls (F(1,26) = 13.2, p = 0.001) 
and this decrease was not enhanced by administration of 1 mg/kg CCG-203769. 
 
Effects of RGS4 on DOR-Mediated Antidepressant-like Effects 
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The effects of SNC80 on immobility time in the forced swim test were evaluated in 
RGS4 +/+, +/R4, and R4/R4 mice (Figure 2.2A). Two-way ANOVA revealed a significant 
interaction (SNC80 dose [0.1-10 mg/kg only] X genotype, F(10,102) = 6,1, p < 0.0001) and a 
significant main effect of SNC80 dose (F(5,102) = 17.1, p < 0.0001), but no effect of genotype. 
In all three genotypes, SNC80 produced a U-shaped dose effect curve with similar magnitude of 
maximum effect, albeit at different doses (+/+: 10 mg/kg, +/R4 and R4/R4: 1 mg/kg). Both the 
descending and ascending limbs of this U-shaped curve were shifted to the left in both the +/R4 
and R4/R4 mice, indicating an increase in the potency, but not efficacy, of SNC80.  
To further probe the role of RGS4 in DOR-mediated antidepressant-like effects, the 
effects of SNC80 were evaluated in the tail suspension test (TST) in RGS4 +/+, +/R4, and R4/R4 
mice (Figure 2.2B). Doses up to 3.2 mg/kg SNC80 produced dose-dependent decreases in 
immobility in RGS4 +/+, +/R4, and R4/R4 mice; however, the largest dose tested failed to 
further decrease immobility. The effect of SNC80 dose was significant (F(4,98) = 18.2, p < 
0.0001) but there was only a non-significant trend for genotype (F(2,98) = 2.8, p = 0.07) and a 
non-significant SNC80 dose X genotype interaction. Although the magnitude of effect of SNC80 
on immobility reduction was slightly greater in the R4/R4 mice, this effect was not statistically 
significant. There was no difference in the magnitude of effect or shape of the dose effect curve 
in RGS4 heterozygous mutant mice treated with SNC80 30 or 60 minutes prior to the tail 
suspension test. 
 
Effects of RGS4 on DOR-Mediated Convulsions 
 SNC80 produced dose-dependent increases in convulsion frequency in RGS4 +/+, +/R4, 
and R4/R4 mice (Figure 2.3A). These convulsions were blocked by pretreatment with 3.2 mg/kg 
naltrindole in all genotypes (Figure 2.3B). There were no significant differences in the 
frequency, time of onset, and duration (data not shown) of convulsions in the +/R4 or R4/R4 
animals relative to wild-type littermates for a given dose of SNC80. There were also no 
differences between genotypes in the frequency of convulsions produced by the chemical 
convulsant pentylenetetrazol (PTZ; data not shown). 
To evaluate whether SNC80-induced convulsions are centrally-mediated, C57BL6 wild-
type mice were pretreated with the nonspecific opioid antagonist naltrexone or its peripherally-
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restricted analog N-methylnaltrexone (Figure 2.3C). 10 mg/kg and 32 mg/kg SNC80 produced 
convulsions that were blocked by pretreatment with naltrexone but not N-methylnaltrexone.  
 
Effects of RGS4 on DOR-Mediated Antihyperalgesia 
In order to determine if RGS4 can modulate DOR-mediated antihyperalgesia, the potency 
of SNC80 to reverse NTG-induced thermal hyperalgesia in RGS4 +/+, +/R4, and R4/R4 mice 
was assessed (Figure 2.4B). There were no differences between genotypes in the baseline tail 
withdrawal latencies prior to NTG treatment (+/+: 39.1 ± 2.4 s, +/R4: 43.3 ± 2.2 s, R4/R4: 42.4 ± 
2.3 s). Administration of 10 mg/kg NTG (ip) significantly decreased tail withdrawal latency to a 
similar degree in all genotypes (+/+: 7.4 ± 1.2 s, +/R4: 9.0 ± 1.1 s, R4/R4: 8.3 ± 0.6 s). Reduction 
of RGS4 enhanced the ability of SNC80 to increase tail withdrawal latency. Two-way ANOVA 
revealed a significant interaction (SNC80 dose X genotype, F(8,92) = 2.6, p =  0.01), as well as 
significant main effects of SNC80 dose (F(4,92) = 25.3, p < 0.0001) and genotype (F(2,92) = 
20.9, p < 0.0001). This enhanced effect of SNC80 resulted in a pronounced leftward shift (~10-
fold) in the dose response curve, indicating a significant increase in the potency of SNC80.  
To evaluate the role of DOR in SNC80-induced antihyperalgesia, C57BL6 wild-type 
mice were pretreated with the DOR selective antagonist naltrindole (Figure 2.4C). Two-way 
repeated measure ANOVA revealed a significant interaction (NTI dose X time point, F(2,20) = 
8.7, p = 0.01), and a significant main effect of NTI dose (F(1,10) = 5.0, p = 0.05), indicating a 
DOR-mediated effect. To evaluate the relative contributions of central and peripheral opioid 
receptors to SNC80-induced antihyperalgesia, C57BL6 wild-type mice were pretreated with the 
nonselective opioid antagonist naltrexone or the peripherally-limited analog N-methylnaltrexone 
(Figure 2.4D). Two-way repeated measure ANOVA revealed a significant interaction 
(pretreatment X time point, F(4,32) = 3.0, p = 0.03) and a significant main effect of pretreatment 
(F(2,16) = 4.4, p = 0.03). Post-hoc analysis further revealed that SNC80-induced increases in tail 
withdrawal latency were blocked by naltrexone (p < 0.01) but not by N-methylnaltrexone. 
 
Elimination of RGS4 Enhances DOR Signaling But Does Not Affect DOR Number  
 To evaluate the effect of RGS4 on DOR signaling in brain, whole striatum of R4/R4 mice 
or their wild-type littermate controls were treated with the DOR agonist SNC80 (1.0 µM) and 
phosphorylation of ERK1/2 was examined. This concentration of SNC80 did not increase 
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ERK1/2 phosphorylation in striatum as compared with vehicle treatment in RGS4 +/+ mice but 
caused a marked increase in ERK1/2 phosphorylation as compared with vehicle in striatal tissue 
from R4/R4 knockout mice (125 ± 67%)  (Figure 2.5B).   
Western blot analysis confirmed a lack of RGS4 protein expression in the RGS4 
knockout mice (Figure 2.5A).  However, it is possible that the enhanced behavioral effects of 
SNC80 in RGS4 mutant mice are due to elevated density or agonist affinity of DOR relative to 
their wild-type littermates. Saturation binding with the radiolabeled DOR agonist [3H]DPDPE 
was performed with brain tissue from RGS4 +/+, +/R4, and R4/R4 mice to assess potential 
changes in DOR density and agonist affinity (Figure 2.5C). There were no significant differences 
in total receptor number between the three genotypes (Table 2.1). There were also no changes in 
the Kd of [
3H]DPDPE for DOR in the RGS4 mutant mice (Table 2.1). 
 
Discussion 
 In this report, we demonstrate that RGS4 differentially regulates DOR-mediated 
behaviors acting as a negative regulator of some, but not all, behavioral outcomes. In the acetic 
acid stretch assay (antinociception), SNC80 alleviated acid-induced stretches at a relatively large 
dose (32 mg/kg) consistent with previous reports (Broom et al. 2002b; Gallantine and Meert 
2005; Negus et al. 2012). Large doses of SNC80 (10 and 32 mg/kg) were also required to reverse 
NTG-induced thermal hyperalgesia, consistent with the findings of Pradhan et al. (2014). 
SNC80-induced antinociception, but not hyperalgesia, was blocked by pretreatment with the 
peripherally-restricted opioid antagonist N-methylnaltrexone, suggesting peripheral DOR likely 
mediate the antinociceptive actions of SNC80 in the acetic acid stretch assay while central DOR 
mediated SNC80-induced antihyperalgesia. Genetic loss of RGS4 or acute pharmacological 
inhibition of RGS4 with CCG-203769 increased the potency of SNC80 to produce 
antinociception and antihyperalgesia. The fact that significant changes are seen in both the 
heterozygote (+/R4) and homozygote (R4/R4) knockout mice suggests that DOR-mediated 
signaling is exquisitely sensitive to the actions of RGS4. Overall, these observations suggest that 
central and peripheral DOR within various pain pathways and neurocircuits are likely co-
localized with RGS4 proteins to modulate DOR signaling and DOR-induced pain relief in vivo.    
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Interestingly, pharmacological inhibition or genetic alterations of RGS4 did not alter the 
potency of the MOPr agonist morphine to produce antinociception in the acetic acid stretch 
assay, similar to other reports in vivo (Han et al. 2010) and in SHSY5Y cells endogenously 
expressing opioid receptors and RGS4 proteins (Wang et al. 2009). However, RGS4 proteins 
have been shown to alter MOPr signaling in vitro and in vivo, depending on the cell type, brain 
region, or MOPr agonist used. For example, RGS4 was shown to regulate the rewarding effects 
of morphine and the antinociceptive effects of the MOPr agonists methadone and fentanyl but 
not morphine (Han et al. 2010).  In addition, in heterologous expression systems, RGS4 can 
regulate MOPr signaling (Leonidas et al. 2009; Talbot et al. 2010). Together, these data suggest 
that RGS4 proteins may have the capacity to regulate MOPr-mediated signaling and behaviors as 
long as the appropriate proteins are co-expressed in the necessary cells and/or circuits.  
 It has previously been shown that loss of RGS4 altered SNC80 action in the mouse 
forced swim test (Stratinaki et al. 2013); however, this report only examined a single dose of 
SNC80 (5 mg/kg) in one behavioral assay making it difficult to fully assess the role of RGS4 in 
SNC80-induced antidepressant-like effects. This report sought to expand on those findings and 
shows that RGS4 plays a complex role in regulating DOR-mediated antidepressant-like effects, 
depending on the type of assay employed. In wild-type mice, SNC80 produced decreases in 
immobility in the forced swim and tail suspension tests, consistent with previous work showing 
that DOR agonists produce antidepressant-like effects in these assays (Broom et al. 2002a; Naidu 
et al. 2007; Saitoh et al. 2011). In both assays, SNC80 produced U-shaped dose effect curves, 
such that larger doses of SNC80 (10 mg/kg in TST, 32 mg/kg in FST) failed to produce 
significant antidepressant-like effects. The lack of effect observed with large SNC80 doses is 
possibly due to competing behaviors, such as possible recovery from recent seizure events or 
excessive locomotor stimulation (Chu Sin Chung et al. 2015). In the forced swim test, 
elimination of RGS4 shifted the entire U-shaped function to the left, indicating that RGS4 acts as 
a negative regulator of DOR-mediated antidepressant-like effects (as well as any possible 
competing behaviors) in this assay. However, loss of RGS4 activity had no significant effect on 
SNC80-induced antidepressant-like effects in the tail suspension test. It is unlikely that different 
SNC80 pretreatment times were responsible for the different effects of RGS4 in the TST and 
FST because even longer pretreatments (60 min) in the TST did not alter the effects of SNC80 in 
RGS4 heterozygous knockout mice. Also, relatively similar doses of SNC80 produced 
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antidepressant-like effects in both assays, so it is unlikely that differences in receptor occupancy 
or efficacy requirement could account for this disparity between the TST and FST.  Differences 
in drug responses between these two behavioral assays have been reported previously (for review 
see, Cryan et al. 2005), and it has been argued that the biological substrates underlying these 
behaviors may be distinct. Therefore, it is possible that the behavioral effects of SNC80 in the 
two assays may be governed by separate brain regions, behavioral mechanisms, and/or signaling 
pathways that are differentially dependent on RGS4 signaling.   
 In contrast to the role of RGS4 in antinociception, antihyperalegsia, and antidepressant-
like effects in the FST (but not the TST), reductions in RGS4 did not alter the potency of SNC80 
to induce convulsions. The ability of RGS4 to alter a behavioral endpoint does not appear to be 
correlated with the potency of SNC80, since similar doses of SNC80 were required to produce 
convulsions, antinociception, and antihyperalgesia in wild-type mice. Alternatively, if we 
measured more subtle electroencephalographic activity rather than overt convulsive behavior 
(Jutkiewicz et al. 2006), we may have been able to observe an effect of RGS4 on this endpoint 
and future studies will evaluate this.  In the present study, convulsions were evaluated in mice 
that received injections of NTG to induce hyperalgesia in an attempt to reduce the number of 
animals used. While NTG did not alter the frequency or nature of SNC80-induced convulsions in 
wild-type mice, it is possible that NTG masked or altered the dependency of convulsions on 
RGS4. Nevertheless, these results suggest that RGS4 selectively regulates signaling pathways 
mediating different behavioral outcomes of DOR activation and is likely not involved in the 
signaling mechanisms mediating convulsions.   
  RGS proteins function as negative regulators of G protein signaling by binding Gα-GTP 
and accelerating Gα-mediated GTP hydrolysis which returns Gα to an inactive state. Loss of 
RGS function should prolong the lifetime of active Gα and increase downstream signaling. 
Consistent with this theory, the present study demonstrated that loss of RGS4 potentiated DOR-
mediated: 1) phosphorylation of ERK1/2 in mouse striatal tissue, 2) peripheral antinociception, 
3) central antihyperalgesia, and 4) antidepressant-like effects measured in the FST, likely due to 
prolongation of DOR-mediated G protein signaling and amplification of downstream effectors. 
These findings identify some specific DOR-mediated behaviors and downstream signaling 
molecules in certain brain regions that are regulated by RGS4.  However, DOR-mediated 
convulsions and behaviors in the TST were not significantly altered by reductions in RGS4, 
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suggesting that different signaling pathways may underlie these behaviors. DOR and RGS4 may 
not be expressed in the same neurons within circuits mediating these behavioral outcomes. For 
example, while DOR and RGS4 are both highly expressed in the hippocampus, the proposed 
origin site of convulsions (Simmons and Chavkin 1996; Chung et al. 2015), they may not be co-
expressed in the same cells and, therefore, may not functionally interact. It is also possible that 
RGS proteins other than RGS4 modulate the DOR-induced convulsive effects and behaviors in 
the TST. Alternatively, these specific DOR-mediated behaviors may be generated by a G 
protein-independent, arrestin-mediated signaling mechanism (Violin 2014). Previous studies 
have demonstrated that DOR activation leads to signaling through G protein-dependent and -
independent pathways (Bradbury et al. 2009; Charfi et al. 2014; Charfi et al. 2015). However, 
there are few reports connecting these distinct signaling mechanisms to specific behavioral 
outputs (Chiang et al. 2016; Pradhan et al. 2016). In conclusion, this study demonstrates that 
RGS4 differentially regulates SNC80-induced behaviors, suggesting that different molecular or 
cellular signaling pathways or neurocircuitry mediate these behavioral outcomes. Future work 
will investigate the role of other RGS proteins in DOR-mediated convulsions and the underlying 





Bates EA, Nikai T, Brennan KC, Fu YH, Charles AC, Basbaum AI, Ptáček, Ahn AH (2010). 
Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. 
Cephalalgia 30: 170-178. 
 
Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, Wang Q, Huang 
XP, Traynor JR, Husbands SM, Morari M, Neubig RR (2015) Selectivity and anti-Parkinson’s 
potential of thiadiazolidinone RGS4 inhibitors. ACS Chem Neurosci 6: 911-919.  
 
Bradbury FA, Zelnik JC, Traynor JR (2009). G protein independent phosphorylation and 
internalization of the delta-opioid receptor. J Neurochem 109:1526-1535. 
 
Broom DC, Guo L, Copp A, Husbands SM, Lewis JW, Woods JH, Traynor JR (2000). BU48 a 
novel buprenorphine analog that exhibits δ-opioid-mediated convulsions but not δ -opioid- 
mediated antinociception in mice. J Pharmacol Exp Ther 294:1195-1200. 
 
Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002a). Nonpeptidic 
delta-opioid receptor agonists reduce immobility in the forced swim assay in rats.  
Neuropsychopharmacology 26: 744-755. 
 
Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, Traynor JR (2002b). Comparison of 
receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and 
antinociception in mice. J Pharmacol Exp Ther 303: 723-729. 
 
Charfi I, Nagi K, Mnie-Filali O, Thibault D, Balboni G, Schiller PW, Trudeau LE, Pineyro G 
(2014). Ligand- and cell-dependent determinants of internalization and cAMP modulation by 
delta opioid receptor (DOR) agonists. Cell Mol Life Sci 71:1529-1546. 
 
Charfi L, Audet N, Bagheri Tudashki H, Pineyro G (2015). Identifying ligand-specific signaling 
within biased responses: focus on d opioid receptor ligands. Br J Pharmacol 172:435-448. 
 
Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, De Costa BR, Mosberg HI, Woods 
JH (1993). Convulsive effects of systemic administration of the delta opioid agonist BW373U86 
in mice. J Pharmacol Exp Ther 267: 888-895.  
 
Chiang T, Sansuk K, van Rijn RM (2016). β-Arrestin 2 dependence of δ opioid receptor agonists 
is correlated with alcohol intake. Br J Pharmacol 173: 332-343.  
 
Chu Sin Chung P, Keyworth HL, Martin-Garcia E, Charbogne P, Darcq E, Bailey A, Filliol D, 
Matifas A, Scherrer G, Ouagazzal AM, Gaveriaux-Ruff C, Befort K, Maldonado R, Kitchen I, 
Kieffer BL (2015). A novel anxiogenic role for the delta opioid receptor expressed in 
GABAergic forebrain neurons. Biol Psychiatry 77: 404-415.  
 
Chu Sin Chung P, Kieffer BL (2013). Delta opioid receptors in brain function and disease. 




Chung PC, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E, Befort K, Kieffer BL (2015). 
Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-
induced seizures. Behav Brain Res 278: 429-434.  
 
Cifelli C, Rose RA, Zhang H, Voigtlaender-Bolz J, Bolz SS, Backx PH, Heximer SP (2008). 
RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node. Circ Res 
103: 527-35.  
 
Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing 
antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci and 
Biobehav Rev 29:571-625. 
 
Gallantine EL, Meert TF (2005). A comparison of the antinociceptive and adverse effects of mu-
opioid agonist morphine and the delta-opioid agonist SNC80. Basic Clin Pharmacol Toxicol 97: 
39-51.  
 
Gu Z, Jiang Q, Yan Z (2007). RGS4 modulates serotonin signaling in prefrontal cortex and links 
to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol 71: 1030-1039.  
 
Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D, Birnbaum S, Young K, 
Neve R, Nestler EJ, Zachariou V (2010). Brain region specific actions of regulator G protein 
signaling 4 oppose morphine reward and dependence but promote analgesia. Biol Psychiatry 
67:761-769.  
 
Hollinger S, Hepler JR (2002). Cellular regulation of RGS proteins: modulators and integrators 
of G protein signaling. Pharmacol Rev 54: 527-559. 
 
Hong EJ, Rice KC, Calderon SN, Woods JH, Traynor, JR (1998). Convulsive behavior of 
nonpeptide δ-opioid ligands: comparison of SNC80 and BW373U86 in mice. Analgesia 3: 269-
276. 
 
Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH (2006). The convulsive and 
electroencephalographic changes produced by nonpeptidic δ-opioid agonists in rats: comparison 
with pentylenetetrazol. J Pharmacol Exp Ther 317:1337-1348. 
 
Leontiadas LJ, Papakonstantinou MP, Georgoussi Z (2009). Regulator of G protein signaling 4 
confers selectivity to specific G proteins to modulate mu- and delta-opioid receptor signaling. 
Cell Signal 21: 1218-1228.  
 
Lutz PE, Kieffer BL (2013). Opioid receptors: distinct roles in mood disorders. Trends Neurosci 
36: 195-206. 
 
Naidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD (2007). NIH 11082 
produces antidepressant-like activity in the mouse tail-suspension through a delta opioid receptor 
mechanism of action. Eur J Pharmacol 566: 132-136. 
49 
 
Negus SS, Rosenberg MB, Altarifi AA, O’Connell RH, Folk JE, Rice KC (2012). Effects of the 
δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation 
(ICSS) in rats. J Pain 13: 317-327.  
 
Nomoto S, Adachi K, Yang LX, Hirata Y, Muragachi S, Kiuchi K (1997). Distribution of RGS4 
mRNA in mouse brain shown by in situ hybridization. Biochem Biophys Res Commun 241: 
281-287.  
 
Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for 
antidepressants. Arch Int Pharmacodyn Ther 229: 327-336. 
 
Pradhan AA, Smith ML, Zyuzin J, Charles A (2014). δ-opioid receptor agonists inhibit migraine 
related hyperalgesia, aversive state, and cortical spreading depression in mice. Br J Pharmacol 
171: 2375-2384. 
 
Pradhan AA, Perro J, Walwyn WM, Smith ML, Vicente-Sanchez A, Segura L, Bana A, Keiffer 
BL, Evans CJ (2016). Agonist-specific recruitment of arrestin isforms differentially modify delta 
opioid receptor function. J Neurosci 36:3541-3551. 
 
Saitoh A, Sugiyama A, Nemoto T, Fujii H, Wada K, Oka J, Nagase H, Yamada M (2011). The 
novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive 
effects in mice without producing convulsions. Behav Brain Res 223: 271-279.  
 
Simmons ML, Chavkin C (1996). Endogenous opioid regulation of hippocampal function. Int 
Rev Neurobiol 39: 145-196. 
 
Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for 
screening antidepressants in mice. Psychopharmacology 85:367-370. 
 
Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C, Russo SJ, Vialou V, Caldarone 
BJ, Tamminga CA, Nestler EJ, Zachariou V (2013). RGS4 is a crucial modulator of 
antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci USA 
110: 8254-8259. 
 
Talbot JN, Roman DL, Clark MJ, Roof RA, Tesmer JJ, Neubig RR, Traynor JR (2010). 
Differential modulation of my-oioid receptor signaling to adenylyl cyclase by regulators of G 
proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent. J Neurochem 
112:1026-1034. 
 
Turner EM, Blazer LL, Neubig RR, Husbands SM (2012). Small molecule inhibitors of regulator 
of G protein signalling (RGS) proteins. ACS Med Chem Lett 9: 146-150.  
 
Violin JD (2014). Biased ligands at mu and delta opioid receptors: targeting selective signalling 
to develop improved therapeutics. International narcotic research conference 2014, pp22. 
50 
 
Wang Q, Liu-Chen LY, Traynor JR (2009). Differential modulation of mu- and delta-opioid 














1 1 0 1 0 0


































































V e h ic le
3 .2  m g /k g  S N C 8 0
* #
* #




































































V e h ic le
0 .1 m g /k g  M o rp h in e
*
*




























+ / + + /R 4 R 4 /R 4
N T I





































Figure 2.1 Effects of RGS4 on opioid-mediated antinociception in the mouse acetic acid stretch 
assay. Number of acetic acid-induced stretches after treatment with (A) different doses of SNC80 
in RGS4 wild-type and mutant (+/R4, R4/R4) mice, (B) different doses of the RGS4 inhibitor 
CCG-203769 in combination with an inactive SNC80 dose (3.2 mg/kg) or SNC80 vehicle in 
C57BL6 wild-type mice, (C) SNC80 following pretreatment with 3.2 mg/kg of the DOR 
antagonist naltrindole in RGS4 wild-type and mutant mice  (D) the MOPr agonist morphine in 
RGS4 wild-type and mutant mice, (E) different doses of  the RGS4 inhibitor CCG-203769 in 
combination with a low dose of morphine or vehicle, (F) SNC80 following pretreatment with 3.2 
mg/kg of the opioid antagonist naltrexone or 10 mg/kg of the peripherally-restricted opioid 
antagonist N-methylnaltrexone. n = 6-9 mice per group for all experiments. Data are shown as 
average per treatment condition with standard error of the mean (sem). * p < 0.05 compared to 
vehicle treatment in the same genotype, *** p < 0.001 compared to vehicle treatment, # p < 0.05 
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Figure 2.2 Effects of RGS4 on DOR-mediated antidepressant-like effects. Immobility scores of 
RGS4 wild-type and mutant (+/R4, R4/R4) mice following treatment with different doses of 
SNC80 in the (A) forced swim test, and (B) tail suspension test. n = 6-10 mice per group and 
data are shown as average per treatment condition with standard error of the mean (sem). * p < 
0.05 compared to vehicle treatment in the same genotype, # p < 0.05 compared to wild-type mice 
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Figure 2.3 Frequency of SNC80-induced convulsions (A) in RGS4 wild-type and mutant (+/R4, 
R4/R4) mice, (B) following pretreatment with 3.2 mg/kg of the DOR antagonist naltrindole in 
RGS4 wild-type and mutant mice, (C) following pretreatment with 3.2 mg/kg of the opioid 
antagonist naltrexone or 10 mg/kg of the peripherally-restricted opioid antagonist N-
methylnaltrexone in C57BL6 wild-type mice. n = 6-12 mice per group for all experiments and 
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Figure 2.4. (A) Diagrams of NTG-induced hyperalgesia test schedule, depending on antagonist 
treatment. (B) Effect of different doses of SNC80 on tail withdrawal latency in NTG treated 
RGS4 wild-type and mutant (+/R4, R4/R4) mice. (C) Effect of the DOR antagonist NTI or 
vehicle on SNC80-induced antihyperalgesia in C57BL6 mice. (D) Effect of pretreatment with 
vehicle, 3.2 mg/kg NTX, or 10 mg/kg MNTX on SNC80-induced antihyperalgesia in C57BL6 
mice. n = 6-10 mice per group for all experiments and data are shown as average per treatment 
condition with standard error of the mean (sem). * p < 0.05 compared to vehicle or NTX 





Figure 2.5. (A) RGS4 protein expression by Western blot. Lysates were prepared from striatal 
brain tissue from wildtype and R4/R4 mice as compared with RGS4 purified protein. (B) 
SNC80-mediated stimulation of ERK1/2 phosphorylation over vehicle control in striatal tissue 
from wild-type and R4/R4 mice (t(5.4)=1.9, p=0.05). (C) Saturation binding of [3H]DPDPE to 
membranes prepared from forebrains of RGS4 wild-type or mutant (+/R4, R4/R4) mice. Points 





Table 2.1 DOR density and agonist affinity in RGS4 knockout mice 
 
Genotype Bmax (fmol/mg ± sem) [
3H] DPDPE Kd (nM) 
+/+ 124 ± 8 2 ± 0.4 
+/R4 165 ± 12 2 ± 0.5 










 G protein-coupled receptors (GPCRs) are a diverse family of membrane bound receptors 
that regulate a wide array of biological functions. Canonically, GPCRs regulate these processes 
through activation of G proteins which subsequently interact with a variety of downstream 
effectors. Following agonist activation, a GPCR is phosphorylated by G protein-coupled receptor 
kinases (GRKs) and internalized by arrestins. In recent years, it has become apparent that GPCRs 
can signaling through G protein-independent mechanisms (Galandrin et al. 2007) by directly  
recruiting arrestins that can also promote signaling from GPCRs (Reiter et al. 2012). 
Furthermore, ligands that act at the same orthosteric site on a receptor can stabilize distinct active 
conformations that preferentially signal through distinct G protein or arrestin subtypes. This 
phenomenon, known as functional selectivity or biased agonism, has been observed with 
multiple GPCRs including the β2 adrenergic receptor (Drake et al. 2008), the CB1 cannabinoid 
receptor (Hudson et al. 2010), as well as mu, kappa, and delta opioid receptors (Pradhan et al. 
2012). 
 The delta opioid receptor (DOR) is a class A GPCR and interacts with Gαi/o proteins. 
Activation of DOR in rodents has been shown to produce antinociception, antihyperalgesia, and 
antidepressant-like effects without the constipation, respiratory depression, and abuse liability 
observed with mu opioid receptor agonists (for review see Chu Sin Chung and Kieffer 2013). In 
addition, some DOR agonists also cause convulsions, which has limited their clinical utility 
(Comer et al. 1993; Hong et al. 1998).  
 The signaling pathways that bring about DOR-mediated behaviors are only beginning to 
be understood. Targeted knockdown of specific G protein subunits using antisense nucleotides 
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inhibited DOR-mediated spinal and supraspinal antinociception in mice, implicating multiple 
Gαi/o subtypes in the regulation of these effects (Standifer et al. 1996; Sánchez-Blázquez and 
Gárzon 1998). Loss of regulator of G protein signaling 4 (RGS4) potentiated the antinociceptive, 
antihyperalgesic, and antidepressant-like effects of the DOR agonist SNC80 suggesting that 
these behaviors are generated through G protein signaling (Dripps et al. 2017). However, this 
study also found that the frequency of SNC80-induced convulsions was not altered in RGS4 
knockout mice suggesting that DOR-mediated convulsions may signal through a G protein-
independent mechanism. Loss of arrestin 2 (β-arrestin 1) increased the potency of SNC80 to 
induce mechanical antihyperalgesia, whereas loss of arrestin 3 (β-arrestin 2) produced acute 
tolerance to the antihyperalgesic effects of the DOR agonists ARM390 and JNJ20788560 
(Pradhan et al. 2016). 
 Use of a drug that is biased towards producing the analgesic and antidepressant-like 
effects of DOR could be an effective strategy for improving the safety and clinical utility of 
DOR agonists. A detailed understanding of the intracellular signaling pathways that give rise to 
DOR-mediated behaviors, and DOR-mediated convulsions in particular, is critical for the 
development of such drugs. Therefore, to gain a better understanding of the downstream 
signaling mechanisms that give rise to DOR-mediated behaviors, we evaluated the potency of 
SNC80 to produce antihyperalgesia, antidepressant-like effects, and convulsions in Gαo 
heterozygous knockout mice, Gαo RGS-insensitive heterozygous knock-in mice, as well as 
arrestin 2 and arrestin 3 knockout mice. 
 
 
Materials and Methods 
Subjects 
All animal use procedures complied with the Guide for the Care and Use of Laboratory 
Animals by the National Institutes of Health, and were approved by the University of Michigan 
Institutional Committee on the Use and Care of Animals. All animal studies are reported in 
accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny 
et al., 2010; McGrath et al., 2010). Mice were housed in groups of four to five animals per cage. 
All mice were used between 8 and 15 weeks of age at time of experiment and weighed 16-32 g. 
Mice had free access to standard lab chow and water and were maintained in a temperature- and 
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humidity-controlled environment on a 12-h dark/light cycle with lights on at 7:00 AM. Mice 
were tested only once, and all analyses are between-subject with the exception of the hot plate 
test (within-subject analysis). 
The arrestin 3 knockout mouse strain (Arrb2 tm1Rjl/J) was obtained from The Jackson 
Laboratory (Bar Harbor, Maine, https://www.jax.org/strain/011130). Arrestin 2 knockout mice 
(Arrb1tm1jse, https://www.jax.org/strain/011131) were provided by Dr. Amynah A. Pradhan 
(University of Illinois at Chicago). Gαo RGS-insensitive heterozygous knock-in mice (Goldstein 
et al. 2009) were obtained from Dr. Richard Neubig and Gαo knockout mice were obtained from 
Dr. Richard Mortensen (Duan et al. 2007). Mice were backcrossed at least six generations into a 
C57BL/6 background and maintained in-house as heterozygote harem (1 male, 2 female) 
breeding groups except for arrestin 2 knockout mice which were maintained as homozygote 
harem breeding groups. Wild-type littermates (+/+) were used as controls for all strains except 
arrestin 2 knockout mice in which case arrestin 3 wild-type littermates were used. For studies in 
which transgenic mice were not required, C57BL/6N mice (17-30g) were obtained from Envigo 
(formerly Harlan, Indianapolis, IN).  
 
Drugs 
All drugs were injected at a volume of 10 ml·kg-1unless otherwise noted. SNC80 ((+)-4-
[(R)--((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide) 
was dissolved in 1 M HCl and diluted in sterile water to a concentration of 3% HCl. 
Nitroglycerin (NTG) was provided by Dr. Adam Lauver (Department of Pharmacology and 
Toxicology, Michigan State University) at a concentration of 5mg/ml and was diluted in saline. 
Desipramine hydrochloride (Sigma-Aldritch, St. Louis, MO), sumatriptan succinate (Sigma-
Aldritch, St. Louis, MO) and morphine sulfate (RTI International, Research Triangle Park, NC) 
were dissolved in saline. All drugs were given subcutaneously (sc) except for NTG which was 
administered via intraperitoneal (ip) injection. 
 
Forced Swim Test 
 The forced swim test (FST) was adapted from Porsolt et al (1977) and performed as 
previously described (Dripps et al. 2017). Briefly, sixty min after SNC80 (0.1, 0.32, 1, 3.2, 10, or 
32 mg·kg-1) or vehicle injection, each mouse was placed in a 4L beaker filled with 15 cm of 
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25±1°C water and its behavior was recorded for 6 min using a Sony HDR-CX220 digital 
camcorder. Videos were analyzed by individuals blind to the experimental conditions and the 
amount of time the animals spent immobile was quantified. Immobility was defined as the mouse 
not actively traveling through the water and making only movements necessary to stay afloat. 
The time the mouse spends immobile after the first 30 sec of the assay was recorded. 
 
Nitroglycerin-Induced Hyperalgesia 
The NTG-induced hyperalgesia assay was adapted from Bates et al (2010) using 
modifications described in Pradhan et al (2014) and performed as previously described (Dripps 
et al. 2017). In brief, male and female C57RGS4 mice were used to evaluate NTG-induced 
hyperalgesia. Hyperalgesia was assessed by immersing the tail (~5cm from the tip) in a 46°C 
water bath and determining the latency for the animal to withdraw its tail with a cut-off time of 
60 sec. After determining baseline withdrawal latencies, 10 mg·kg-1 NTG (ip) was administered 
to each animal. Tail withdrawal latency was assessed again 1 hr after NTG administration. At 90 
min post-NTG, animals received an injection of SNC80 (0.32, 1, 3.2, 10, or 32 mg·kg-1) or 
vehicle, and mice were observed continuously in individual cages for 30 min to observe for 
convulsions (see section below). Tail withdrawal latencies were assessed again 30 min after 
SNC80 administration.  
 
SNC80-Induced Convulsions  
Mice were observed continuously for 30 min in individual cages for convulsions. NTG 
treatment had no effect on the frequency or nature of SNC80-induced convulsions (data not 
shown). Convulsions were comprised of a tonic phase characterized by sudden tensing of the 
musculature and extension of the forepaws followed by clonic contractions that extended the 
length of the body. Convulsions were followed by a period of catalepsy that lasted 2-5 min after 
which the animals were hyperlocomotive but otherwise indistinguishable from untreated 
controls. The severity of each convulsion was quantified using the following modified Racine 
scale: 1- teeth chattering or face twitching; 2- head bobbing or twitching; 3- tonic extension or 
clonic convulsion lasting less than 3 sec; 4- tonic extension or clonic convulsion lasting longer 
than 3 sec; 5- tonic extension or clonic convulsion lasting more than 3 sec with loss of balance. 
Post-convulsion catalepsy-like behavior was assessed by placing a horizontal rod under the 
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forepaws of the mouse and a positive catalepsy score was assigned if the mouse did not remove 
its forepaws after 30 sec. 
 
Hot Plate Test 
The hot plate test was adapted from Lamberts et al. (2011). Briefly, male wild-type 
C57BL/6N mice were placed on a 52°C hot plate and the latency to lick forepaw(s) or jump was 
measured with a cutoff time of 60s in order to prevent tissue damage. To determine baseline 
latency, mice were placed on the hot plate 30 min after each of two injections of saline. 
Following an injection of 32 mg·kg-1 morphine, latency was assessed every 30 min. 
 
DOR Saturation Binding 
Mice were decapitated, whole brain was removed, and membranes were freshly prepared 
as previously described (Broom et al. 2002a).  Protein concentrations were determined with a 
BCA assay kit (Thermo Scientific, Rockford, IL). Specific binding of the DOR agonist 
[3H]DPDPE was determined as described using 10µM of the opioid antagonist naloxone to 
define non-specific binding (Broom et al. 2002a). Reactions were incubated for 60 min at 26ºC 
and stopped by rapid filtration through GF/C filter mats using a MLR-24 harvester (Brandel, 
Gaithersburg, MD). Bound [3H]DPDPE was determined by scintillation counting and Bmax and 
Kd values calculated using nonlinear regression analysis with GraphPad Prism version 6.02 
(GraphPad, San Diego, CA).  
 
Data Analysis 
 The data and statistical analysis comply with the recommendations on experimental 
design and analysis in pharmacology (Curtis et al. 2015). All data analysis was performed using 
GraphPad Prism version 6.02 (GraphPad, San Diego, CA). Post hoc analysis was conducted 
using the Tukey’s post hoc test to correct for multiple comparisons. For all tests, level of 
significance ( was set to 0.05. All values in the text are reported as mean ± SEM. ED50 values 
were calculated using GraphPad Prism version 6.02 by extrapolating the 50% maximum effect 
from the straight line analysis of the averaged treatment group data used to generate each dose 





DOR-Mediated Behaviors in Gαo RGS-Insensitive Mice 
 It has previously been demonstrated that loss of RGS4 potentiates DOR-mediated 
antihyperalgesia and antidepressant-like effects, but not DOR-mediated convulsions (Dripps et 
al, 2017). To further investigate the signaling mechanisms involved in these behaviors, we 
characterized the behavioral effects of SNC80 in Gαo RGS-insensitive heterozygous mice. The 
Gαo RGS-insensitive heterozygous mice have one copy of GNAO1 with a G184S point mutation 
that prevents binding of all RGS proteins to Gαo and should enhance signaling from those G 
proteins (Goldstein et al. 2009; Lamberts et al. 2013). First, the potency of SNC80 to reverse 
NTG-evoked thermal hyperalgesia was evaluated in Gαo RGS-insensitive heterozygous mice 
(+/GS) and their wild-type littermates (+/+; Figure 3.1A). The +/GS mice did not differ 
significantly from wild-type littermates in their baseline tail withdrawal latencies prior to NTG 
treatment (+/+: 42.4 ± 2.5 s, +/GS: 41.4 ± 1.4 s). Administration of 10 mg·kg-1 NTG 
significantly decreased tail withdrawal latency to a similar degree in both genotypes (+/+: 6.1 ± 
1.3 s, +/GS: 5.4 ± 0.3 s). Two-way ANOVA revealed a significant interaction (SNC80 dose X 
genotype, F(5,60) = 7.61, p <  0.0001), as well as significant main effects of SNC80 dose 
(F(5,60) = 56.15, p < 0.0001) and genotype (F(1,60) = 53.07, p < 0.0001). There was an 
approximately 4-fold leftward shift in the SNC80 dose effect curve and a slight increase in the 
maximum effect observed in the +/GS mice compared with their wild-type littermates. Overall, 
the potency and efficacy of SNC80 to increase tail withdrawal latency was enhanced in Gαo 
RGS-insensitive heterozygous mice.  
 The potency of SNC80-induced antidepressant-like effects in Gαo RGS-insensitive 
heterozygous mice was evaluated in the FST (Figure 3.1B). In the absence of drug treatment, 
+/GS mice had lower immobility scores than wild-type littermates. SNC80 produced 
significantly lower immobility scores in +/GS mice compared to wild-type littermates. Two-way 
ANOVA revealed significant main effects of SNC80 dose ([vehicle and 0.32-10 mg/kg only] 
F(4,51) = 17.7, p < 0.0001) and genotype (F(1,51) = 45.34, p < 0.0001), as well as a significant 
interaction (SNC80 dose X genotype, F(4,51) = 5.74, p = 0.0007). Due to the basal differences in 
immobility scores, scores were normalized to a percentage relative to vehicle treated mice of the 
appropriate genotype (Figure 3.1C). Two-way ANOVA revealed significant main effects of 
SNC80 dose ([vehicle and 0.32-10 mg/kg only] F(4,51) = 17.1, p < 0.0001) and genotype 
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(F(1,51) = 4.80, p = 0.0331), as well as a significant interaction (SNC80 dose X genotype, 
F(4,51) = 6.23, p = 0.0004). To investigate whether Gαo RGS-insensitive heterozygous mice 
were hyperresponsive to a wider array of antidepressive drugs, the effects of the tricyclic 
antidepressant desipramine were evaluated in the FST (Figure 3.1D). Although desipramine 
produced decreases in immobility (main effect of desipramine dose: F(2,31) = 12.43, p = 
0.0001), there was no effect of genotype and no significant interaction. 
 Although loss of RGS4 did not alter SNC80-induced convulsions, other RGS proteins 
may play a role in regulating this behavior. Therefore, we evaluated SNC80-induced convulsions 
in the strain of mice with Gαo subunits insensitive to all RGS proteins. The severity of SNC80-
induced convulsions in Gαo RGS-insensitive wild-type and heterozygous mice were evaluated 
using a modified Racine scale (Figure 3.1E). SNC80 produced similar dose-dependent increases 
in convulsion severity in both genotypes. If a convulsion occurred, it was typically within 15 min 
of SNC80 administration and lasted 6-15 sec. 
 It is possible that the enhanced behavioral effects of SNC80 in Gαo RGS-insensitive 
heterozygous mice are due to elevation of density or agonist affinity of DOR relative to their 
wild-type littermates. To evaluate potential changes in receptor density or agonist affinity, 
saturation binding with the radiolabeled DOR agonist [3H]DPDPE was performed using brain 
tissue from Gαo RGS-insensitive +/+ and +/GS mice. There were no significant differences in 
total receptor number of the +/GS mice compared to wild-type littermates (Table 3.1; Figure 
3.1F). In addition, there were no changes in the affinity of [3H]DPDPE for DOR in the Gαo RGS-
insensitive heterozygous mice. 
  
DOR-Mediated behaviors in Gαo Heterozygous Knockout Mice 
 SNC80-induced antihyperalgesia and antidepressant-like effects were enhanced in Gαo 
RGS-insensitive heterozygous mice, suggesting that these behaviors are mediated by Gαo 
proteins. To further evaluate the role of Gαo in DOR-mediated behaviors, we characterized DOR-
mediated antihyperalgesia, antidepressant-like effects, and convulsions in Gαo heterozygous 
knockout mice. Gαo null mice were produced infrequently and rarely survived to weaning 




 Prior to NTG administration, there were no significant differences in tail withdrawal 
latency in wild-type and Gαo heterozygous knockout mice (+/+: 41.2 ± 1.8 s, +/-: 40.3 ± 2.0 s). 
Administration of 10 mg·kg-1 NTG produced similar decreases in tail withdrawal latency in both 
genotypes (+/+: 4.9 ± 0.5 s, +/-: 4.1 ± 0.3 s). In Gαo wild-type mice, SNC80 produced dose-
dependent increases in tail withdrawal latency following NTG administration (Figure 3.2A). This 
effect was abrogated in Gαo heterozygous knockout mice. Two-way ANOVA revealed 
significant main effects of SNC80 dose [vehicle and 10-56 mg·kg-1 only] (F(3,40) = 23.55, p < 
0.0001) and genotype (F(1,40) = 167.6, p < 0.0001), as well as a significant interaction (SNC80 
dose X genotype, F(3,40) = 22.40, p < 0.0001). To investigate whether the antihyperalgesic 
effects of non-DOR drugs were altered in Gαo heterozygous knockout mice, the effects of the 5-
HT1B/1D agonist sumatriptan on NTG-induced thermal hyperalgesia were examined (Figure 
3.2B). Sumatriptan produced similar robust increases in tail withdrawal latency in wild-type and 
Gαo heterozygous knockout mice (two-way ANOVA main effect of sumatriptan dose: F(2,30) = 
91.28, p < 0.0001 but no main effect of genotype and no interaction). 
 In the FST, SNC80 produced significant decreases in immobility in both the Gαo wild-
type and heterozygous knockout mice (Figure 3.2C; Two-way ANOVA main effect of SNC80 
dose: F(4,50) = 22.05, p < 0.0001)). However, there were no significant differences between 
genotypes in the immobility scores produced in response to a given dose of SNC80. SNC80 also 
produced similar dose-dependent increases in convulsion severity in Gαo wild-type and 
heterozygous knockout mice (Figure 3.2D).  
 The diminished effect of SNC80 on NTG-induced hyperalgesia in Gαo heterozygous 
knockout mice could be due to decreased density of or agonist affinity at DOR relative to wild-
type littermates. To evaluate potential changes in receptor density or agonist affinity, saturation 
binding with the radiolabeled DOR agonist [3H]DPDPE was performed using brain tissue from 
Gαo wild-type and heterozygous knockout mice. There were no significant differences in total 
receptor number or affinity of [3H]DPDPE for DOR in the Gαo heterozygous knockout mice 
relative to wild-type littermates (Table 3.1; Figure 3.2E). 
 
DOR-Mediated Behaviors in Arrestin 2 and Arrestin 3 Knockout Mice 
 To investigate G protein-independent mechanisms, we evaluated SNC80-induced 
antihyperalgesia, antidepressant-like effects, and convulsions in arrestin 2 and arrestin 3 
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knockout mice. There were no significant differences in SNC80-induced antihyperalgesia, 
antidepressant-like effects, or convulsions in the arrestin 3 knockout mice compared to wild-type 
and heterozygote knockout littermates (Figures 3.3A-C). However, the increase in hot-plate 
latency produced by a single bolus dose of 32 mg·kg-1 morphine in the 52 ºC hot plate test was 
potentiated in arrestin 3 knockout mice (Figure 3.3D) consistent with previously published data 
(Bohn et al. 1999; Two-way repeated measures ANOVA: main effects of time (F(6,90) = 64.11, 
p < 0.0001), genotype (F(2,15) = 13.95, p = 0.0004), and a significant interaction (F(12,90) = 
6.89, p < 0.0001). 
 In arrestin 2 knockout mice, SNC80-induced increases in tail withdrawal latency 
following NTG administration were similar to wild-type controls (Figure 3.4A). Arrestin 2 
knockout mice had no significant differences in SNC80-induced decreases in immobility in the 
forced swim test relative to wild-type mice (Figure 3.4B). In contrast, SNC80-induced 
convulsions were profoundly altered in arrestin 2 knockout mice. The potency of SNC80 to 
induce convulsions was significantly increased in arrestin 2 knockout mice as evidenced by a 
leftward shift in the dose response curve (Figure 3.4C). Two-way ANOVA revealed significant 
effects of genotype (F(2,62) = 17.83, p < 0.0001), SNC80 dose (F(4,62) = 87.05, p < 0.0001), 
and a significant interaction (F(8,62) = 7.04, p < 0.0001). In addition, several arrestin 2 knockout 
mice had multiple convulsions in response to a single dose of SNC80 (Figure 3.4D). These 
subsequent convulsions were similar in nature to the initial SNC80-induced convulsions, 
consisting of both tonic and clonic phases followed by a brief (2-5 min) period of catalepsy. 
 
Discussion 
 In this report, we sought to further elucidate the downstream signaling mechanism that 
give rise to DOR-mediated behaviors. We found that Gαo and arrestins differentially regulate the 
antihyperalgesia, antidepressant-like effects, and convulsions produced by the DOR agonist 
SNC80. In the NTG-induced thermal hyperalgesia assay, SNC80 produced antihyperalgesia in 
wild-type mice at doses of at least 10 mg·kg-1, consistent with previous studies (Pradhan et al. 
2014; Dripps et al. 2016). SNC80 also decreased in immobility in the forced swim test, 
consistent with the well-established antidepressant-like effects of DOR agonists (Broom et al. 
2002b; Naidu et al. 2007; Saitoh et al. 2011). RGS proteins negatively regulate G protein 
signaling by binding Gα-GTP and accelerating Gα-mediated GTP hydrolysis which returns Gα 
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to an inactive state. This function prolongs the lifetime of active Gα and increase downstream 
signaling.  The potency of SNC80 to produce antihyperalgesia and antidepressant-like effects 
was significantly increased in the Gαo RGS-insensitive heterozygous mice. These data indicate 
that these DOR-mediated behaviors signal through Gαo and are negatively regulated by RGS 
proteins, consistent with our previous finding that RGS4 negatively regulates these behaviors 
(Dripps et al. 2017). Furthermore, these enhanced effects of SNC80 were observed in mice with 
only one mutant copy of Gαo, demonstrating that DOR-mediated signaling in vivo is highly 
sensitive to the effects of RGS proteins. Interestingly, the magnitude of these behavioral changes 
are consistent with those seen in RGS4 knockout mice, suggesting that other RGS proteins likely 
do not play a significant role in regulating the antihyperalgesic and antidepressant-like effects of 
DOR. We hypothesize that the enhanced DOR-mediated antihyperalgesia and antidepressant-like 
effects observed in the +/GS mice are likely due to prolongation of DOR-mediated G protein 
signaling and amplification of downstream effectors.  
 To confirm the role of Gαo in DOR-mediated behaviors, we examined the behavioral 
effects of SNC80 in Gαo heterozygous knockout mice. SNC80-induced antihyperalgesia was 
abolished in Gαo heterozygous knockout mice, suggesting that Gαo is required for the 
antihyperalgesic effects of DOR. Furthermore, this profound effect was produced by only a 50% 
reduction in Gαo, indicating that DOR-mediated antihyperalgesia likely requires robust 
amplification of downstream signaling. It is possible that larger doses of SNC80 could produce 
antihyperalgesia in Gαo heterozygous knockout mice, however such doses are likely to be 
nonselective. Taken together, our findings indicate that Gαo plays a critical role in mediating 
signaling required for DOR-mediated antihyperalgesia. 
 In contrast, decreased expression of Gαo did not affect DOR-mediated antidepressant-like 
effects in the forced swim test. DOR could be capable of signaling through other G proteins in 
order to produce antidepressant-like effects and compensate for the reduction in Gαo expression. 
Alternatively, it is possible that the efficacy requirement for DOR-mediated antidepressant-like 
effects is relatively low compared to that for DOR-mediated antihyperalgesia in which case one 
functional copy of GNAO1 and approximately 50% of Gαo protein subunits (Lamberts et al. 
2011) could be sufficient to produce a full response in the forced swim test. Broom et al. (2002a) 
proposed that the efficacy requirement for DOR-mediated antinociception was higher than that 
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required for convulsions. The relative efficacy requirement for antidepressant-like effects has not 
been evaluated and should be investigated in future studies. 
 In the present study, DOR-mediated convulsions were not altered in Gαo RGSi and Gαo 
knockout mice. In addition, we previously observed that SNC80-induced convulsions were 
unaltered in RGS4 knockout mice (Dripps et al. 2017). Therefore, we explored the hypothesis 
that SNC80-induced convulsions are produced by a G protein-independent, arrestin-mediated 
mechanism. Although class A GPCRs are thought to preferentially interact with arrestin 3 
(Oakley et al. 2000), no significant changes in DOR-mediated behaviors, including convulsions, 
were observed in arrestin 3 knockout mice. It should be noted that these data are the result of 
acute administration of SNC80 and it is possible that arrestin 3 could play a role in regulating the 
effects of repeated doses of SNC80. This observation is consistent with previous reports that 
found that loss of arrestin 3 in mice did not alter the analgesic profile of DOR agonists and had 
no effect on the enhanced coupling of DOR to voltage-dependent calcium channels observed in 
the Complete Freund’s Adjuvant model of chronic inflammatory pain (Pradhan et al. 2013; 
Pradhan et al. 2016). Because we saw no change in DOR-mediated behaviors in arrestin 3 
knockout mice, we evaluated morphine-induced antinociception in the hot plate assay as a 
positive control. As first shown in Bohn et al. (1999), we observed potentiation of morphine-
induced antinociception in arrestin 3 knockout mice. Overall, our findings indicate that arrestin 3 
is not required for DOR-mediated antihyperalgesia, antidepressant-like effects, or convulsions. 
 In arrestin 2 knockout mice, we observed no changes in the effects of SNC80 in response 
to NTG-induced thermal hyperalgesia.  However, the effects of SNC80 on CFA-induced 
mechanical hyperalgesia were potentiated in arrestin 2 knockout mice (Pradhan et al. 2016). It is 
possible that the DOR-mediated responses to these distinct pain modalities are differentially 
regulated by arrestin 2. In contrast to the antihyperalgesic effects, the convulsive effects of 
SNC80 were strongly enhanced in arrestin 2 knockout mice. The potency of SNC80 to induce 
convulsions was enhanced in arrestin 2 knockout mice, suggesting that arrestin 2 acts as a 
negative regulator of DOR-mediated convulsions. Secondly, arrestin 2 knockout mice convulsed 
multiple times in response to a single dose of SNC80. Tolerance to DOR-mediated convulsions 
is typically acute and long lasting (Comer et. al 1993; Hong et al. 1998). In addition, the changes 
in the electroencephalographic waveform produced by SNC80 return to normal baseline activity 
following the end of catalepsy (Jutkiewicz et al. 2006). To our knowledge, this is the first report 
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of multiple convulsive events in response to a DOR agonist in rodents. One possible explanation 
for this observation is that loss of arrestin 2 produces these behavioral changes by upregulating 
DOR trafficking to the cell membrane resulting in enhanced DOR signaling (Mittal et al. 2013). 
However, DOR-mediated antihyperalgesia and antidepressant-like effects were not significantly 
altered in arrestin 2 knockout mice. Therefore, it is possible that the behavioral effects of SNC80 
are differentially regulated by arrestin 2 due to differences in regional expression, behavioral 
mechanisms, and/or signaling pathways. Alternatively, arrestin 2 could be necessary for the rapid 
desensitization and tolerance to the convulsive effects of SNC80. Thus, loss of arrestin 2 could 
allow signaling pathways that would normally be terminated to persist and produce multiple 
convulsive events. Future work will examine whether arrestin 2 also regulates tolerance to other 
behavioral effects of DOR agonists. 
 Overall, our data demonstrate a role for Gαo, but not arrestins, in regulating the acute 
antihyperalgesic and antidepressant-like effects of DOR. However, DOR-mediated convulsions 
appear to be negatively regulated by arrestin 2 and were not altered by manipulations to Gαo 
function. Taken together, these findings suggest that different signaling pathways underlie the 
convulsive effects of DOR relative to the antihyperalgesic and antidepressant-like effects. 
Perhaps due in part to this phenomenon, multiple DOR agonists have been shown to not produce 
convulsions at doses far exceeding those needed to produce antinociception and antidepressant-
like effects (Le Bourdonnec et al. 2008; Saitoh et al. 2011; Chung et al. 2015). However, the 
properties of DOR agonists that determine their convulsive nature remain unclear. Future work 
will continue to investigate the signaling mechanisms responsible for the behavioral effects of 




Bates EA, Nikai T, Brennan KC, Fu YH, Charles AC, Basbaum AI et al. (2010). Sumatriptan 
alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 30: 170-
178. 
 
Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999). Enhanced 
morphine analgesia in mice lacking beta-arrestin 2. Science 286: 2495-2498. 
 
Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, Traynor JR (2002a). Comparison of 
receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and 
antinociception in mice. J Pharmacol Exp Ther 303: 723-729. 
 
Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002b). Nonpeptidic 
delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. 
Neuropsychopharmacology 26: 744-755. 
 
Chu Sin Chung P, Kieffer BL (2013). Delta opioid receptors in brain function and disease. 
Pharmacol Ther 140: 112-120.  
 
Chung PC, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E et al. (2015). Delta opioid 
receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced 
seizures. Behav Brain Res 278: 429-434. 
 
Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, De Costa BR et al. (1993). 
Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J 
Pharmacol Exp Ther 267: 888-895.  
 
Curtis MJ, Bond RA, Spina D, Ahluwaila A, Alexander SPA, Giembycz MA et al. (2015). 
Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J 
Pharmacol 172: 3461-3471. 
 
Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ (2008). beta-arrestin-
biased agonism at the beta2-adrenergic receptor. J Biol Chem 283: 5669-5676. 
 
Dripps IJ, Wang Q, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM (2017). The role of 
regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. 
Psychopharmacology 234: 29-39. 
 
Duan SZ, Christie M, Milstone DS, Mortensen RM (2007). Go but not Gi2 or Gi3 is required for 
muscarinic regulation of heart rate and heart rate variability in mice. Biochem Biophys Res 
Commun 357: 139-143. 
 
Galandrin S, Oligny-Longpré, Bouvier, M (2007). The evasive nature of drug efficacy: 




Goldstein BL, Nelson BW, Xu K, Luger EJ, Pribula JA, Wald JM, et al. (2009). Regulator of G 
protein signaling protein suppression of Gαo protein-mediated α2A adrenergic receptor inhibition 
of mouse hippocampal CA3 epileptiform activity. 
 
Hong EJ, Rice KC, Calderon SN, Woods JH, Traynor, JR (1998). Convulsive behavior of 
nonpeptide δ-opioid ligands: comparison of SNC80 and BW373U86 in mice. Analgesia 3: 269-
276. 
 
Hudson BD, Hébert TE, Kelly MEM (2010). Ligand- and heterodimer-directed signaling of the 
CB1 cannabinoid receptor. Mol Pharmacol 77: 1-9. 
 
Jutkiewicz EJ, Baladi MG, Folk JE, Rice KC, Woods JH (2006). The convulsive and 
electroencephalographic changes produced by nonpeptidic δ-opioid agonists in rats: comparison 
with pentylenetetrazol. J Pharmacol Exp Ther 317: 1337-1348. 
 
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Animal research: reporting 
in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579. 
 
Lamberts JT, Jutkiewicz EM, Mortensen RM, Traynor JR (2011). Mu-opioid receptor coupling 
to Gαo plays an important role in opioid antinociception. Neuropsychopharmacology 36: 2041-
2053. 
 
Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH et al. (2008). Potent, 
orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-
diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem 
51: 5893-5896. 
 
McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals 
(ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193. 
  
Mittal N, Roberts K, Pal K, Bentolila LA, Fultz W, Minasyan A et al. (2013). Select G-protein-
coupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and β-arrestin 1 
pathway. Cell Rep 5: 1010-1021. 
 
Naidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD (2007). NIH 11082 
produces antidepressant-like activity in the mouse tail-suspension through a delta opioid receptor 
mechanism of action. Eur J Pharmacol 566: 132-136. 
 
Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS (2000). Differential affinities of visual 
arrestin, βarrestin1, and βarrestin1 for GPCRs delineate two major classes of receptors. J Biol 
Chem 275: 17201-17210 
 
Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for 




Pradhan AA, Smith ML, Kieffer BL, Evans CJ (2012). Ligand-directed signalling within the 
opioid receptor family. Br J Pharmacol 167:960-969. 
 
Pradhan A, Smith M, McGuire B, Evans C, Walwyn W (2013). Chronic inflammatory injury 
results in increased coupling of delta opioid receptors to voltage-gated Ca2+ channels. Mol Pain 
9:8 doi: 10.1186/1744-8069-9-8 
 
Pradhan AA, Smith ML, Zyuzin J, Charles A (2014). δ-opioid receptor agonists inhibit migraine 
related hyperalgesia, aversive state, and cortical spreading depression in mice. Br J Pharmacol 
171: 2375-2384. 
 
Pradhan AA, Perro J, Walwyn WM, Smith ML, Vicente-Sanchez A, Segura L et al. (2016). 
Agonist-specific recruitment of arrestin isforms differentially modify delta opioid receptor 
function. J Neurosci 36:3541-3551. 
 
Reiter E, Ahn S, Shukla AK, Lefkowitz RJ (2012). Molecular mechanisms of β-arrestin-biased 
agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52: 179-197 
 
Saitoh A, Sugiyama A, Nemoto T, Fujii H, Wada K, Oka J et al. (2011). The novel δ opioid 
receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice 
without producing convulsions. Behav Brain Res 223: 271-279. 
 
Sánchez-Blázquez, P, Gárzon J (1998). Delta opioid receptor subtypes activate inositol-signaling 
pathways in the production of antinociception. J Pharmacol Exp Ther 285: 820-827. 
 
Standifer KM, Rossi GC, Pasternak, GW (1996). Differential blockade of opioid analgesia by 
antisense oligodeoxynucleotides directed against various G protein alpha subunits. Mol 
Pharmacol 50: 293-298. 
 
Xie Z, Li Z, Guo L, Ye C, Li J, Yu X et al. (2007). Regulator of G protein signaling proteins 

































































































































































































Figure 3.1. (A) Effect of different doses of SNC80 on tail withdrawal latency in NTG treated 
Gαo RGS-insensitive wild-type (+/+) and heterozygous (+/GS) mice (B,C) Immobility scores of 
Gαo RGS-insensitive +/+ and +/GS mice in response to SNC80 in the forced swim test expressed 
as (B) raw immobility scores or (C) immobility scores normalized to a percentage of the scores 
of vehicle treated mice of the appropriate genotype. (D) Effects of desipramine on immobility 
scores of Gαo RGS-insensitive +/+ and +/GS mice in the forced swim test (E) Severity of 
SNC80-induced convulsions in Gαo RGS-insensitive +/+ and +/GS mice (F) Saturation binding 
of [3H]DPDPE to membranes prepared from forebrains of Gαo RGS-insensitive +/+ or +/GS 
mice. Each point represents tissue from 1 mouse assayed in triplicate. n = 5-7 mice per group for 
all experiments. Data are shown as average per treatment condition with standard error of the 
mean (sem). * p < 0.05 compared to vehicle treatment in the same genotype, # p < 0.05 
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Figure 3.2. Tail withdrawal latencies in NTG treated Gαo wild-type (+/+) and heterozygous 
knockout (+/-) mice in response to (A) SNC80 or (B) sumatriptan. (C) Effects of SNC80 on 
immobility scores of Gαo +/+ and +/- mice in the forced swim test. (D) Severity of SNC80-
induced convulsions in Gαo +/+ and +/- mice. (E) Saturation binding of [
3H]DPDPE to 
membranes prepared from forebrains of Gαo +/+ and +/- mice.  Each point represents tissue 
from 1 mouse assayed in triplicate. n = 5-6 mice per group for all experiments. Data are shown 
as average per treatment condition with standard error of the mean (sem). * p < 0.05 compared to 
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Figure 3.3. (A) Effects of SNC80 on tail withdrawal latencies in NTG treated arrestin 3 wild-
type (+/+), heterozygous (+/-), and homozygous (-/-) knockout mice. (B) Immobility scores of 
arrestin 3 +/+, +/-, and -/- mice in the forced swim test following treatment with SNC80. (C) 
Severity of SNC80-induced convulsions in arrestin 3 +/+, +/-, and -/- mice (D) Time course of 
the effects of morphine on hot-plate latency in arrestin 3 +/+, +/-, and -/- mice. n = 6-7 mice per 
group for all experiments. Data are shown as average per treatment condition with standard error 
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Figure 3.4. (A) Effects of SNC80 on tail withdrawal latencies in NTG treated arrestin 2 wild-
type (+/+) and knockout (-/-) mice. (B) Immobility scores of arrestin 2 +/+ and -/- mice in the 
forced swim test following treatment with SNC80.  (C) Severity of SNC80-induced convulsions 
in arrestin 3 +/+ and -/- mice. (D) Number of SNC80-induced convulsions observed in arrestin 3 
+/+ and -/- mice.  n = 6 mice per group for all experiments. Data are shown as average per 
treatment condition with standard error of the mean (sem). * p < 0.05 compared to vehicle 


















Table 3.1. DOR density and agonist affinity in Gαo RGSi and Gαo knockout mice 
Genotype Bmax (fmol mg-1 ± sem) [3H] DPDPE Kd (nM ± sem) 
Gαo RGSi +/+ 99 ± 6 2.5 ± 0.5 
Gαo RGSi +/GS 90 ± 5 1.7 ± 0.3 
Gαo +/+ 111 ± 11 2.1 ± 0.6 







Pharmacological Properties of Delta Opioid Receptor-Mediated 




 The delta opioid receptor (DOR) is a class A GPCR that couples to inhibitory Gαi/o 
proteins. Activation of DOR has been shown to elicit a number of behavioral effects. DOR 
agonists produce antinociception and antihyperalgesia in mice (Hong et al., 1998; Pradhan et al., 
2014), rats (Gallantine and Meert 2005; Fraser et al., 2000), and monkeys (Negus et al. 1998; 
Brandt et al. 2001). They have also been shown to produce antidepressant-like effects in a 
number of rodent models (for review, see Lutz and Kieffer, 2013). Some, but not all, DOR 
agonists also produce convulsions (Comer et al., 1993; Hong et al., 1998).  
 To better understand the pharmacological properties mediating behavioral effects of DOR 
agonists, we sought to compare directly two structurally distinct DOR ligands that differ in 
intrinsic efficacy: the piperazinyl benzamide SNC80 and the morphinan derivative BU48. 
SNC80 is the prototypical nonpeptidic DOR agonist. It is highly efficacious at stimulating G 
protein activation in vitro in C6 glioma cells (Clark et al. 1997) and ex vivo (Jutkiewicz et al. 
2004). In vivo, SNC80 has been shown to produce antihyperalgesia (Pradhan et al. 2014), 
antidepressant-like effects (Saitoh et al. 2004), and convulsions (Hong et al. 1998) in mice. 
BU48 is less efficacious than SNC80 in vitro, producing approximately 40% stimulation of 
GTPγS binding relative to SNC80 in C6 glioma cells expressing DOR (Broom et al. 2000). This 
report also found that BU48 produces DOR-mediated convulsions but did not produce DOR-
mediated antinociception (Broom et al. 2000), suggesting that the efficacy requirement for DOR-
mediated convulsions is low relative to that for antinociception. Consistent with this hypothesis, 
small doses (3 and 10 mg/kg sc) of the DOR irreversible antagonist naltrindole-5’-isothiocyanate 
(5’-NTII) antagonized the antinociceptive effects of the DOR agonist BW373U86 but did not 
decrease the frequency of BW373U86-induced convulsions in NIH Swiss mice (Broom et al. 
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2002a). In another study, SNC80 was significantly more potent at producing decreases in 
immobility in the rat forced swim test compared to the partial agonist SNC162 (Jutkiewicz et al.
2004), but these two compounds produced convulsions with similar potencies, also suggesting 
that the efficacy requirement for DOR-mediated convulsions may be low relative to that for 
antidepressant-like effects. However, the relationship of agonist efficacy to the behavioral effects 
of DOR agonists has not been thoroughly evaluated. 
Therefore, the present study evaluated the role of agonist efficacy, DOR receptor reserve, 
and DOR receptor populations involved in DOR-mediated behaviors. To do this, we compared 
the behavioral effects of the DOR full agonist SNC80 and the DOR partial agonist BU48. Effects 
of receptor reserve were assessed by comparing the shifts in the dose response curves for 
SNC80-induced antihyperalgesia, antidepressant-like effects, and convulsions in DOR 
heterozygous knockout mice and mice treated with the irreversible DOR antagonist 5’-NTII 
treated wild-type mice as compared with controls.  We also evaluated the ability of the 
competitive DOR antagonist naltrindole (NTI) to attenuate SNC80-induced antihyperalgesia, 
antidepressant-like effects, and convulsions to determine antagonist potency and potential 
mechanisms of antagonism. 
 
Materials and Methods 
Subjects 
All animal use procedures complied with the Guide for the Care and Use of Laboratory 
Animals by the National Institutes of Health, and were approved by the University of Michigan 
Institutional Committee on the Use and Care of Animals. Mice were housed in groups of four to 
five animals per cage. All mice were used between 8 and 15 weeks of age at time of experiment 
and weighed 16-32 g. Mice had free access to standard lab chow and water and were maintained 
in a temperature- and humidity-controlled environment on a 12-h dark/light cycle with lights on 
at 7:00 AM. Mice were tested only once, and all analyses are between-subject. 
The Oprd1tm1Kff/J mouse strain was obtained from The Jackson Laboratory (Bar Harbor, 
Maine, https://www.jax.org/strain/007557; Filliol et al., 2000). Mice maintained in-house as 
heterozygote pair or harem (1 male, 2 female) breeding groups. Male and female mice were used 
in all studies. Wild-type littermates (+/+) were used as controls in all experiments involving 
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C57DOR heterozygote (+/-) and homozygote (-/-) knockout mice. For studies in which 
transgenic mice were not required, C57BL/6N mice were obtained from Envigo (formerly 
Harlan, Indianapolis, IN).  
 
Forced Swim Test 
 The forced swim test was adapted from Porsolt et al (1977) and performed as previously 
described (Dripps er al. 2017). In brief, sixty min after SNC80 (0.32, 1, 3.2, 10 mg/kg sc), BU48 
( 1, 3.2, 10 mg/kg sc) or vehicle injection, each mouse was placed in a 4L beaker filled with 15 
cm of 25±1°C water and swim sessions were recorded for 6 min using a Sony HDR-CX220 
digital camcorder. Videos were analyzed by individuals blind to the experimental conditions and 
the amount of time the animals spent immobile was quantified. Immobility was defined as the 
mouse not actively traveling through the water and making only movements necessary to stay 
afloat. The time the mouse spends immobile after the first 30 sec of the assay was recorded. 
 
Nitroglycerin-Induced Hyperalgesia 
The NTG-induced hyperalgesia assay was adapted from Bates et al (2010) using 
modifications described in Pradhan et al (2014) and performed as previously described (Dripps 
et al., 2017). Hyperalgesia was assessed by immersing the tail (~5cm from the tip) in a 46°C 
water bath and determining the latency for the mouse to withdraw its tail with a cut-off time of 
60 sec. After determining baseline withdrawal latencies, 10 mg/kg NTG (ip) was administered to 
each animal. Tail withdrawal latency was assessed again 1 hr after NTG administration. At 90 
min post-NTG, animals received an injection of SNC80 (3.2, 10, 32, 100, 180 mg/kg sc), BU48 
(3.2, 10, 32 mg/kg sc) or vehicle, and mice were observed continuously in individual cages for 
20 min to observe for convulsions (see section below). Tail withdrawal latencies were assessed 
again 30 min after SNC80 administration.  
 
SNC80-Induced Convulsions  
Mice were observed continuously in individual cages for convulsions, catalepsy, 
myclonic jerks, stop-and-stare behaviors, wet dog shakes, digging and other normal or abnormal 
behaviors. Convulsions were comprised of a tonic phase characterized by sudden tensing of the 
musculature and extension of the forepaws followed by clonic contractions that extended the 
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length of the body. Convulsions were followed by a period of catalepsy that lasted 2-5 min after 
which the animals were indistinguishable from untreated controls. The severity of each 
convulsion was quantified using the following modified racine scale: 1- teeth chattering or face 
twitching; 2- head bobbing or twitching; 3- tonic extension or clonic convulsion lasting less than 
3 sec; 4- tonic extension or clonic convulsion lasting longer than 3 sec; 5- tonic extension or 
clonic convulsion lasting more than 3 sec with loss of balance. Post-convulsion catalepsy was 
assessed by placing a horizontal rod under the forepaws of the mouse and a positive catalepsy 
score was assigned if the mouse did not remove its forepaws after 30 sec. 
 
DOR Saturation Binding 
Mice were decapitated, whole brain was removed, and membranes were freshly prepared 
as previously described (Broom et al., 2002a).  Protein concentrations were determined with a 
BCA assay kit (Thermo Scientific, Rockford, IL). Specific binding of the DOR agonist 
[3H]DPDPE was determined as described using 10µM of the opioid antagonist naloxone to 
define non-specific binding as described (Broom et al., 2002a). Reactions were incubated for 60 
min at 26ºC and stopped by rapid filtration through GF/C filter mats using a MLR-24 harvester 
(Brandel, Gaithersburg, MD). Bound [3H]DPDPE was determined by scintillation counting. 
 
[35S]GTPγS Binding Assay 
Mouse brain membranes (as prepared above, 10 μg/well) were incubated for 90 min at 26 °C in 
buffer comprising 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 5 mM MgCl2, 100 mM NaCl, 0.1 
nM [35S]GTPγS, 100 μM GDP (guanosine 5-diphosphate) , and 0.4 U/mL adenosine deaminase 
in a final volume of 200 μL. SNC80 or BU48 were also included at appropriate concentrations. 
10 µM SNC80 was used as the maximal standard and assay buffer was used to assess basal 
[35S]GTPγS binding. The reaction was terminated by filtration through glass microfiber GF/C 
filters (Whatman) using a Brandell harvester. The filters were rinsed, dried, and radioactivity was 
determined by scintillation counting. 
 
Data Analysis 
All data analysis was performed using GraphPad Prism version 6.02 (GraphPad, San 
Diego, CA). Unless otherwise indicated, data were compared by two-way ANOVA and Post hoc 
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analysis was conducted using the Tukey’s post hoc test to correct for multiple comparisons. Bmax 
and Kd values were compared by unpaired t test. For all tests, level of significance ( was set to 
0.05. ED50 values were calculated by extrapolating the 50% maximum effect from the straight 
line analysis of the averaged treatment group data used to generate each dose effect function. Ex 




N,N-diethylbenzamide) was dissolved in 1 M HCl and diluted in sterile water to a concentration 
of 3% HCl. BU48 (N-Cyclopropylmethyl-[7alpha,8alpha,2', 3']-cyclohexano-1'[S]-hydroxy-
6,14-endo-ethenotetrahydronororipavine) was dissolved in a solution comprised of 10% ethanol, 
10% Alkamuls EL-620 (Acros Organics, Morris Plains, NJ), and 80% sterile water. NTG was 
provided by Dr. Adam Lauver (Department of Pharmacology and Toxicology, Michigan State 
University) at a concentration of 5mg/ml and was diluted in saline. Naltrindole-5’-isothiocyanate 
(5’-NTII; Sigma-Aldritch, St. Louis, MO) was dissolved in 10% DMSO. Naltrindole (NTI; 
Tocris Bioscience, Pittsburgh, PA) was dissolved in sterile water. 5’-NTII (32 mg/kg) or vehicle 
was injected 24 hrs prior to SNC80 administration. NTI (1, 3.2 mg/kg) or vehicle was injected 30 
min prior to SNC80 administration. All drugs were injected at a volume of 10 mL/kg. All drugs 




Characterization of BU48-Induced Behaviors 
 The DOR partial agonist BU48 has previously been shown to produce DOR-mediated 
convulsions but not DOR-mediated antinociception (Broom et al., 2000). The potential 
antihyperalgesic and antidepressant-like effects of BU48 have not been evaluated. Therefore, we 
sought to further characterize the pharmacological and behavioral effects of BU48 as compared 
with the full DOR agonist SNC80. In mouse forebrain tissue, SNC80 produced robust and dose-
dependent stimulation of [35S]GTPγS binding (EC50: 210 nM; Figure 4.1A). BU48 did not 
produce significant stimulation of [35S]GTPγS binding at concentrations up to 10 µM. In vivo, 
BU48 failed to increase tail withdrawal latency in NTG treated wild-type mice up to a dose of 32 
82 
 
mg/kg whereas SNC80 significantly increased tail withdrawal latency at 10 and 32 mg/kg 
(Figure 4.1B). Two-way ANOVA revealed significant effects of drug (F(1,40) = 118.0, p <  
0.0001), dose (F(3,40) = 50.90, p <  0.0001), and a significant interaction (F(3,40) = 45.41, p < 
0.0001). Additionally, pretreatment with BU48 30 min prior to SNC80 administration prevented 
SNC80-induced increases in tail withdrawal latency in C57BL/6N wild-type mice (Figure 4.1C). 
Two-way ANOVA revealed a significant interaction (BU48 dose X genotype, F(1,20) = 67.83, p 
<  0.0001) and significant main effects of BU48 dose (F(1,20) = 78.38, p <  0.0001) and SNC80 
dose (F(1,20) = 57.97, p <  0.0001). However, in mice lacking regulator of G protein signaling 4 
(RGS4), 32 mg/kg BU48 was able to increase tail withdrawal latencies relative to wild-type 
littermates (Figure 4.1D). Two-way ANOVA revealed significant main effects of BU48 dose 
(F(1,21) = 17.67, p =  0.0004) and genotype (F(1,21) = 12.21, p =  0.0022), as well as a 
significant interaction (BU48 dose X genotype, F(1,21) = 23.46, p <  0.0001).  
 In the forced swim test, BU48 produced dose-dependent decreases in immobility (Figure 
4.1E). Two-way ANOVA revealed only a significant main effect of drug (F(1,42) = 38.48, p <  
0.0001), suggesting a difference in potency and/or efficacy between BU48 and SNC80. To 
evaluate the role of DOR in BU48-induced antidepressant-like effects, C57BL6 wild-type mice 
were pretreated with the DOR selective antagonist NTI (Figure 4.1F). Two-way ANOVA 
revealed a significant main effect of BU48 dose (F(1,21) = 7.77, p = 0.011). BU48-induced 
decreases in immobility were blocked by pretreatment with 3.2 mg/kg NTI (BU48 dose X NTI 
dose, F(1,21) = 13.04, p = 0.0016), indicating a DOR-mediated effect. 
 BU48 produced dose-dependent increases in convulsion severity (Figure 4.2A). As with 
those produced by SNC80, BU48-induced convulsions were comprised of tonic and clonic 
phases that were followed by a period of catalepsy. For a given dose, there were no significant 
differences in the time of onset (Figure 4.2B) or duration (Figure 4.2C) of convulsions produced 
by BU48 and SNC80. BU48-induced convulsions were blocked by pretreatment with 3.2 mg/kg 
NTI, indicating a DOR-mediated effect (Unpaired two-tailed t test: t(10) = 12.85, p < 0.0001; 
Figure 4.2D). 
 
DOR-Mediated Behaviors in DOR Knockout Mice 
Changes in DOR density and agonist affinity in DOR mutant mice were assessed by 
saturation binding in brain tissue with the radiolabeled DOR agonist [3H]DPDPE (Figure 4.3A). 
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Total DOR in heterozygous knockout mice was approximately 40% of that measured for wild-
type mice (Table 4.1). The affinity of [3H]DPDPE for DOR did not differ significantly between 
wild-type and heterozygous knockout mice (Table 4.1). DOR could not be detected in DOR 
homozygous knockout mice.  
To evaluate the efficacy requirements of DOR-mediated behaviors, we compared the 
potency of SNC80 to induce antihyperalgesia, antidepressant-like effects, and convulsions in 
DOR wild-type and heterozygous knockout mice. In a NTG-induced thermal hyperalgesia assay, 
there were no differences between genotypes in the baseline tail withdrawal latencies prior to 
NTG treatment (+/+: 35.7 ± 1.7 s, +/-: 35.6 ± 1.3 s, -/-: 38.9 ± 2.9 s). Administration of 10 mg/kg 
NTG (ip) significantly decreased tail withdrawal latency to a similar degree in all genotypes 
(+/+: 3.6 ± 0.3 s, +/-: 3.6 ± 0.2 s, -/-: 4.1 ± 0.4 s). Overall, the potency of SNC80 to increase tail 
withdrawal latency was significantly decreased in the DOR heterozygous knockout mice as 
evidenced by a 7.1-fold leftward shift in the dose effect curve relative to wild-type mice (Figure 
4.3B; ED50 values: +/+: 14 mg/kg; +/-: 100 mg/kg). Two-way ANOVA comparing the DOR 
wild-type and heterozygous knockout groups revealed a significant interaction (SNC80 dose [0, 
3.2-100 mg/kg only] X genotype, F(4,51) = 7.99, p <  0.0001), as well as significant main effects 
of SNC80 dose (F(4,51) = 23.97, p < 0.0001) and genotype (F(1,51) = 36.92, p < 0.0001).  
SNC80 failed to increase tail withdrawal latency in DOR homozygous knockout mice at a dose 
of 100 mg/kg. 
The potency of SNC80 to reduce immobility time in the forced swim test was evaluated 
in DOR mutant mice (Figure 4.3C). Two-way ANOVA comparing the DOR wild-type and 
heterozygous knockout groups revealed significant main effects of SNC80 dose (F(4,59) = 
34.15, p < 0.0001) and genotype (F(1,59) = 22.20, p < 0.0001), and a significant interaction 
effect (SNC80 dose X genotype, F(4,59) = 4.74, p = 0.0022). The SNC80 dose response curve 
for DOR heterozygous knockout mice shifted approximately 4.2-fold to the right relative to wild-
type mice, indicating a decrease in the potency of SNC80 (ED50 values: +/+: 1.3 mg/kg; +/-: 5.5 
mg/kg). SNC80 failed to reduce immobility in DOR homozygous knockout mice at a dose of 10 
mg/kg. 
The potency of SNC80 to produce convulsive effects was also evaluated in DOR mutant 
mice (Figure 4.3D). Two-way ANOVA comparing the DOR wild-type and heterozygous 
knockout mice revealed significant main effects of SNC80 dose (F(4,51) = 89.68, p < 0.0001) 
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and genotype (F(1,51) = 12.23, p = 0.001), as well as a significant interaction effect (SNC80 
dose X genotype, F(4,51) = 7.83, p < 0.0001). The SNC80 dose response curve for DOR 
heterozygous knockout mice was shifted approximately 1.7-fold to the right relative to wild-type 
mice, indicating a decrease in the potency of SNC80 (ED50 values: +/+: 13 mg/kg; +/-: 22 
mg/kg). SNC80 failed to produce convulsions in DOR homozygous knockout mice at a dose of 
100 mg/kg. 
 
DOR-Mediated Behaviors in 5’-NTII Treated Mice 
 To further explore the efficacy requirements contributing to the behavioral effects of 
DOR agonists, we aimed to decrease DOR numbers by approximately 25%—less receptor loss 
than that observed in the DOR heterozygous knockout mice—using the irreversible DOR 
antagonist 5’-NTII. 24 hr pretreatment with 32 mg/kg 5’-NTII reduced the Bmax of [
3H]DPDPE 
by approximately 30% (Figure 4.4A; Table 4.1). There were no significant differences in the 
affinity of [3H]DPDPE for DOR between treatment groups (Table 4.1). 
 In the NTG-induced thermal hyperalgesia assay, there were no differences in the baseline 
tail withdrawal latencies 24 hrs after 5’-NTII or vehicle pretreatment (vehicle: 37 ± 1.4 s, 5’-
NTII: 41 ± 2.2s). Administration of 10 mg/kg NTG (ip) significantly decreased tail withdrawal 
latency to a similar degree in both treatment groups (vehicle: 4.4 ± 0.5 s, 5’-NTII: 5.2 ± 0.4 s). 
Pretreatment with 32 mg/kg 5’-NTII reduced the potency of SNC80 to increase tail withdrawal 
latency as evidenced by an approximate 3.3-fold rightward shift in the dose response curve 
(Figure 4.4B; ED50 values: vehicle: 13 mg/kg; 5’-NTII: 43 mg/kg). Two-way ANOVA revealed 
a significant interaction (SNC80 dose [0, 10, 32 mg/kg only] X 5’-NTII dose, F(2,29) = 3.80, p =  
0.034), as well as significant main effects of SNC80 dose (F(2,29 = 27.01, p < 0.0001) and 5’-
NTII dose (F(1,29) = 17.04, p = 0.0003). 
 In the forced swim test, pretreatment with 32 mg/kg 5’-NTII alone did not alter 
immobility scores relative to vehicle pretreatment. Pretreatment with 5’-NTII produced an 
approximate 2-fold rightward shift in the SNC80 dose response curve relative to wild-type mice, 
indicating a decrease in the potency of SNC80 (Figure 4.4C; ED50 values: vehicle: 1 mg/kg; 5’-
NTII: 2 mg/kg). Two-way ANOVA revealed a significant interaction (SNC80 dose X 5’-NTII 
dose, F(2,30) = 9.22, p =  0.0008), as well as significant main effects of SNC80 dose (F(2,30 = 
55.36, p < 0.0001) and 5’-NTII dose (F(1,30) = 4.62, p = 0.0398). The severity of SNC80-
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induced convulsions were not significantly altered by pretreatment with 5’-NTII (Figure 4.4D) 
nor did NTII alter the frequency, duration, or time to onset of convulsions (data not shown). 
 
DOR-Mediated Behaviors in NTI Treated Mice 
 The affinity of a competitive antagonist for a given population of receptors should not 
change depending on the output being measured (Kenakin 1982). To further characterize the 
receptor populations mediating SNC80-induced behaviors, we evaluated the ability of small (1 
mg/kg) or large (3.2 mg/kg) doses of the competitive DOR antagonist NTI to block SNC80-
induced behaviors. In a NTG-induced thermal hyperalgesia assay, 10 and 32 mg/kg SNC80 
produced significant increases in tail withdrawal latency in C57BL6 wild-type mice (Figure 
4.5A). Pretreatment with either 1 or 3.2 mg/kg NTI abolished the effects of SNC80 at 10 and 32 
mg/kg. Two-way ANOVA revealed a significant interaction (SNC80 dose X NTI dose, F(4,45) = 
34.44, p <  0.0001), as well as significant main effects of SNC80 dose (F(2,45 = 27.34, p < 
0.0001) and NTI dose (F(2,45) = 130.0, p < 0.0001). 
 In the forced swim test, administration of 1 or 3.2 mg/kg SNC80 significantly decreased 
immobility (Figure 4.5B). SNC80-induced decreases in immobility were blocked by 
pretreatment with 3.2 mg/kg NTI. Pretreatment with 1 mg/kg NTI blocked the decreases in 
immobility produced by the small SNC80 dose (1 mg/kg); however, administration of 3.2 mg/kg 
SNC80 was able to surmount the effects of this low dose of NTI. Two-way ANOVA revealed 
significant main effects of SNC80 dose (F(2,46 = 11.22, p = 0.0001) and NTI dose (F(2,46) = 
23.03, p < 0.0001), and a significant interaction (SNC80 dose X NTI dose, F(4,46) = 8.38, p <  
0.0001). 
 Administration of 10 or 32 mg/kg SNC80 alone produced pronounced convulsions 
(Figure 4.5C). Pretreatment with 1 mg/kg NTI failed to block SNC80-induced convulsions. 
Pretreatment with 3.2 mg/kg NTI eliminated convulsions produced by 10 mg/kg SNC80 and 
significantly decreased the severity of convulsive behavior resulting from administration of 32 
mg/kg SNC80. Two-way ANOVA revealed significant main effects of SNC80 dose (F(2,45 = 
77.91, p < 0.0001) and NTI dose (F(2,45) = 43.68, p < 0.0001), as well as a significant 






 In this report, we sought to explore the pharmacological characteristics differentiating 
some behavioral effects of DOR agonists, such as antihyperalgesia, antidepressant-like and 
convulsive effects. We found that these three behaviors demonstrate a rank order of efficacy 
requirements with convulsions having the lowest requirement, followed by antidepressant-like 
effects and then antihyperalgesia. We also provide pharmacological evidence to suggest that 
these DOR-mediated behaviors are governed by distinct receptor populations. 
 The DOR partial agonist BU48 has previously been shown to elicit DOR-mediated 
convulsions, but not DOR-mediated antinociception (Broom et al., 2000). To further characterize 
the behavioral effects of a DOR partial agonist, we evaluated the potency of BU48 to produce 
DOR-mediated antihyperalgesia, antidepressant-like effects and convulsions. BU48 produced 
dose-dependent increases in convulsion severity with similar potency and efficacy to SNC80, 
though mice treated with 3.2 mg/kg BU48 exhibited some preconvulsive behavior, such as head 
twitches and brief myoclonic jerks. BU48 also produced antidepressant-like effects in the forced 
swim test, albeit with reduced potency relative to SNC80. BU48 also appeared to be less 
efficacious than SNC80 in the forced swim test, consistent with a partial agonist profile, but 
larger doses would need to be tested to fully evaluate this claim. The reduced potency and/or 
efficacy of BU48 in the forced swim test could be due to its activity as a kappa opioid agonist 
which are known to produce prodepressant-like effects (Mague et al., 2003). It would be 
interesting to test whether co-administration of a kappa opioid antagonist would enhance the 
antidepressant-like effects of BU48. Ex vivo, BU48 did not significantly stimulate 35[S]GTPγS 
binding in forebrain tissue, indicating that BU48 is a low efficacy agonist, at least at the level of 
G protein activation. BU48 could act as a full agonist for a different, G protein-independent 
signaling pathway. 
 BU48 not only failed to reverse NTG-induced thermal hyperalgesia in wild-type mice, it 
antagonized SNC80-induced antihyperalgesia. These data further support the claim that BU48 is 
a DOR partial agonist. One alternative explanation is that BU48 is a biased agonist that cannot 
activate the intracellular signaling mechanisms needed to produce antihyperalgesia after 
engaging DOR. However, a large (32 mg/kg) dose of BU48 did produce mild antihyperalgesia in 
RGS4 knockout mice. RGS4 acts as a negative regulator of Gαi/o signaling and has previously 
been shown to enhance the potency of SNC80-induced antihyperalgesia, suggesting that under 
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these conditions BU48 can produce antihyperalgesia through a SNC80-like mechanism. 
Eliminating RGS activity has also been shown to increase the efficacy of MOR partial agonists 
(Clark et al. 2008). Taken together, these data strongly support BU48 as a DOR partial agonist. 
As a partial agonist, BU48 should more readily produce low efficacy requiring behaviors as 
compared to high efficacy requiring behaviors. Therefore, the ability of BU48 to produce DOR-
mediated convulsions with potency comparable to a full agonist is consistent with convulsions 
having a low efficacy requirement. Likewise, BU48 producing antidepressant-like effects with 
reduced potency and failing to produce antihyperalgesia suggests that these behaviors have 
higher efficacy requirements relative to convulsive effects. 
 To further evaluate the role of receptor reserve in DOR-mediated behaviors, we evaluated 
the potency of SNC80 to produce antihyperalgesia, antidepressant-like effects, and convulsions 
in DOR heterozygous knockout mice. In wild-type littermates, SNC80 dose-dependently 
reversed NTG-induced hyperalgesia, consistent with previous reports (Pradhan et al., 2014; 
Dripps et al., 2017). SNC80 also produced decreases in immobility in the forced swim test and 
convulsions which are well established behavioral outputs generated by SNC80 (Broom et al., 
2002; Saito et al., 2004; Dripps et al., 2017). SNC80 failed to produce any of these behaviors in 
DOR homozygous knockout mice, further supporting the idea that these behaviors are 
specifically mediated by DOR. The potency of SNC80 to produce all three of these behaviors 
was significantly reduced in DOR heterozygous knockout mice, with a rank order of efficacy 
requirement: convulsions (1.7-fold) < antidepressant like effects (4.2-fold) < antihyperalgesia 
(7.1-fold). Consistent with the potency changes observed in DOR heterozygous knockout mice, a 
30% reduction in DOR number was sufficient to decrease the potency of SNC80 to elicit 
antihyperalgesia and antidepressant-like effects, but failed to shift the convulsion dose response 
curve. The rank order was consistent with that observed in DOR transgenic mice.  The minimal 
inhibition of SNC80-induced convulsions following significant reduction in DOR number 
suggests that convulsions have a large receptor reserve. A large receptor reserve indicates that 
few receptors need to be activated in order to produce convulsions. Therefore, SNC80-induced 
convulsions likely have a low efficacy requirement. Conversely, SNC80-induced 
antihyperalgesia was particularly sensitive to changes in DOR number suggesting a low receptor 
reserve and high efficacy requirement. The decrease in potency of SNC80-induced 
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antidepressant-like effects was moderate, suggesting an efficacy requirement between that for 
convulsions and antihyperalgesia.  
 Interestingly, the DOR competitive antagonist NTI differentially shifted the dose 
response curves of the observed DOR-mediated behaviors. A competitive antagonist needs to 
occupy 50% of receptor sites before its effects on an agonist can be noticed (Kenakin 2009). It is 
possible that the efficacy requirement for DOR-mediated convulsions is sufficiently low that a 
larger portion of receptors needs to be occupied to observe antagonism. This hypothesis is 
consistent with the previously discussed findings that a 30% loss in DOR (by 5’-NTII) does not 
alter SNC80-induced convulsions but a 60% loss (in DOR heterozygous knockouts) produces 
mild inhibition. This hypothesis is also consistent with the findings of Broom et al. (2002), who 
showed that a 75% reduction in DOR number abolished BW373U86-induced antinociception but 
still produced convulsions in a majority of NIH Swiss mice. 
 Although we did not test enough doses to perform a full pA2 analysis, it is apparent from 
our data that the potencies with which NTI antagonizes DOR-mediated behaviors are distinct. 
For example, 1 mg/kg NTI was sufficient to completely block antihyperalgesia produced by 10 
and 32 mg/kg SNC80 but did not affect convulsions produced by SNC80 at either of those doses.  
Discrepancies in the apparent potency of NTI could be due to differences in the times at which 
these behaviors can be observed. Because we measured the antihyperalgesic (30 min), 
antidepressant-like (60 min), and convulsive (0-30 min) effects of SNC80 at different times, the 
relative concentrations of SNC80 and NTI are likely different and this could impact the observed 
potency of NTI. However, different antagonist potencies across separate behavioral endpoints 
could suggest that different receptor populations mediate these behaviors. There are several 
possibilities regarding what these different receptor populations may represent. The putative 
DOR(1) and (2) subtypes have previously been implicated in mediating the behavioral effects of 
SNC80 (Pacheco et al. 2005; Rawls et al. p2005). The existence of delta-mu and delta-kappa 
receptor heterodimers that engage unique signaling mechanisms has been proposed, and 
activation of these heterodimers would presumably produce distinct behaviors relative to their 
monomeric counterparts (Jordan and Devi 1999; Rozenfeld and Devi 2007). Differences in the 
subcellular localization or internalizing properties of DORs could lead to differences in 
downstream signaling (Pradhan et al. 2009). Different DOR-mediated behaviors could also be 
generated by distinct brain regions with variations in G protein expression or coupling efficiency.  
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 It should be noted that multiple DOR agonists have already been developed that do not 
produce convulsions when given systemically in large doses (Naidu et al., 2007; Vergura et al., 
2008; Le Bourdonnec et al., 2008; Saitoh et al., 2011). If indeed the efficacy requirement for 
convulsions is low, it is critical to determine why these agonists do not produce convulsions. It is 
possible that these nonconvulsive DOR agonists are biased in such a way as to not produce 
convulsions. For example, these drugs may be unable to activate the DOR populations 
responsible for convulsions or may activate different intracellular signaling mechanisms. 
Alternatively, the pharmacokinetic properties of these drugs could inhibit their ability to produce 
convulsions. It has been shown that rapid intravenous infusion of SNC80 improves its potency to 
produce convulsions while slow (20 or 60 min) infusions of SNC80 greatly diminishes potency 
(Jutkiewicz et al., 2005). Nonconvulsive DOR agonists could be absorbed more slowly, thus 
preventing the onset of a convulsion. Future studies will evaluate the pharmacokinetic properties 
of these different DOR agonists 
 In summary, these data suggest that DOR-mediated behaviors have distinct efficacy 
requirements with convulsions having the lowest efficacy requirement, followed by 
antidepressant-like effects and antihyperalgesia, respectively. Furthermore, these DOR-mediated 
behaviors are likely governed by distinct receptor populations as evidenced by the DOR 
competitive antagonist NTI attenuating DOR-mediated behaviors with different potencies. 
Future studies will investigate the nature of these distinct receptor populations and why some 
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Figure 4.1. Characterization of BU48-induced behaviors. (A) Effect of increasing concentrations 
of BU48 or SNC80 on 35[S]GTPγS binding in C57BL6 mouse forebrain tissue. Each point 
represents tissue from 1 mouse assayed in triplicate (n = 3) (B) Effects of different doses of 
BU48 or SNC80 on tail withdrawal latencies in NTG-treated mice. (C) Effect of 10 mg/kg 
SNC80 on tail withdrawal latencies in NTG-treated mice following pretreatment with 10 mg/kg 
BU48 or vehicle. (D) Effects of 32 mg/kg BU48 or vehicle on tail withdrawal latencies in NTG-
treated RGS4 wild-type or knockout mice. (E) Effects of different doses of BU48 or SNC80 on 
immobility scores in the FST. (F) Effect of 10 mg/kg BU48 on immobility in the FST following 
pretreatment with 3.2 mg/kg NTI or vehicle. n = 6-8 mice per group for all behavior 
experiments. Data are shown as average per treatment condition with standard error of the mean 
(sem). * p < 0.05 compared to vehicle treatment, # p < 0.05 compared to wild-type mice with 
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Figure 4.2. Comparison of BU48- and SNC80-induced convulsions. (A) Severity, (B) time of 
onset, and (C) duration of BU48- and SNC80-induced convulsions. (D) Effect of NTI on the 
severity of convulsions produced by 10 mg/kg BU48. n = 6-7 mice per group for all experiments. 
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Figure 4.3. Role of receptor density in DOR-mediated behaviors. (A) Saturation binding of 
[3H]DPDPE to membranes prepared from forebrains of DOR wild-type or mutant mice. Each 
point represents tissue from a single mouse assayed in triplicate (n = 5). (B) Effects of different 
doses of SNC80 on tail withdrawal latencies in NTG-treated DOR wild-type (+/+), heterozygous 
(+/-) and null mutant (-/-) mice. (C) Effects of different doses of SNC80 on immobility scores in 
the FST in DOR wild-type and mutant mice. (D) Severity of SNC80-induced convulsions in 
DOR wild-type and mutant mice as measured by a modified Racine scale. Data are shown as 
average per treatment condition with standard error of the mean (sem). n = 6-7 mice per group 
for all behavior experiments. * p < 0.05 compared to vehicle treatment in the same genotype, # p 
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Figure 4.4. Effects of 5’-NTII on DOR density and DOR-mediated behaviors. (A) Saturation 
binding of [3H]DPDPE to membranes prepared from forebrains of C57BL/6N mice 24 hrs after 
pretreatment with 32 mg/kg 5’-NTII or vehicle (10% DMSO). Each point represents tissue from 
a single mouse assayed in triplicate. (B) Effects of different doses of SNC80 on tail withdrawal 
latencies in NTG-treated mice 24 hrs after pretreatment with 32 mg/kg 5’-NTII or vehicle. (C) 
Effects of different doses of SNC80 on immobility scores in the FST in mice 24 hrs after 
pretreatment with 32 mg/kg 5’-NTII or vehicle. (D) Severity of SNC80-induced convulsions in 
mice as measured by a modified Racine scale 24 hrs after pretreatment with 32 mg/kg 5’-NTII or 
vehicle. Data are shown as average per treatment condition with standard error of the mean 
(sem). n = 5-6 mice per group for all experiments.* p < 0.05 compared to vehicle SNC80 
treatment in the same pretreatment group, # p < 0.05 compared to vehicle pretreatment with 
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Figure 4.5. Potency of NTI to antagonize DOR-mediated behaviors. Effects of different doses of 
SNC80 following pretreatment with different doses of NTI on (A) tail withdrawal latencies in 
NTG-treated mice, (B) immobility scores in the FST, and (C) convulsion severity. Data are 
shown as average per treatment condition with standard error of the mean (sem). n = 6 mice per 
group for all experiments.* p < 0.05 compared to vehicle SNC80 treatment in the same 
pretreatment group, # p < 0.05 compared to 3.2 mg/kg NTI pretreatment with same SNC80 dose. 
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Table 4.1. DOR density and agonist affinity in DOR knockout and 5’-NTII treated mice 
Group Bmax (fmol/mg ± sem) [
3H] DPDPE Kd (nM ± sem) 
DOR +/+ 105 ± 7 2.3 ± 0.4 
DOR +/- 42 ± 3 1.3 ± 0.3 
DOR -/- -3 ± 5 N/A 
C57BL6 DMSO 127 ± 11 2.3 ± 0.4 








 The experiments described in this thesis sought to identify signaling proteins that regulate 
the behavioral effects of DOR agonists. Specifically, the antihyperalgesic, antidepressant-like, 
and convulsive effects of DOR agonists were examined in a number of mouse models. Based on 
the data presented here, the convulsive and therapeutic effects of DOR are likely governed by 
distinct signaling mechanisms. 
 Previous studies have shown that DOR agonists elicit a number of behavioral effects. 
They produce antinociception and antihyperalgesia in mice, rats, and monkeys (Hong et al. 1998; 
Gallantine and Meert 2005; Negus et al. 1998; Pradhan et al. 2014; Fraser et al. 2000; Allen et al. 
2002), antidepressant-like effects in mice and rats (Saitoh et al. 2004; Broom et al. 2002a), and 
convulsions in mice, rats, and monkeys (Comer et al. 1993; Broom et al. 2002b; Dykstra et al. 
1993). Consistent with these findings, the present studies confirm that SNC80 reliably and dose-
dependently produces antinociception, antihyperalgesia, antidepressant-like effects, and 
convulsions in mice. These effects of SNC80 were all blocked by pretreatment with NTI and 
were absent in DOR homozygous knockout mice, further indicating that the therapeutic and 
convulsive effects of SNC80 are all mediated by DOR. Because convulsions are an on-target 
effect of DOR activation, simply using a more selective DOR agonist would likely not be 
sufficient to produce the therapeutic effects of DOR without convulsions. Therefore, we chose to 
investigate potential differences in the pharmacological mechanisms and intracellular signaling 
pathways that give rise to DOR agonist-induced behaviors.  
 
Dissociating the Behavioral Effects of DOR Agonists: Functional Selectivity 
 One potential DOR signaling partner, RGS4, had been shown to negatively regulate DOR 
function in vitro (Leontiadis et al. 2009; Wang et al. 2009). In vivo, the antidepressant-like 
effects of a single 5 mg/kg dose of SNC80 were potentiated in RGS4 knockout mice (Stratinaki 
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et al. 2013). To better understand the role of RGS4 in regulating DOR-mediated behaviors, 
Chapter II of this thesis compared the ability of SNC80 to induce DOR-mediated 
antinociception, antihyperalgesia, antidepressant-like effects, and convulsions in wildtype and 
RGS4 knockout mice. These studies demonstrated that RGS4 differentially regulates DOR-
mediated behaviors acting as a negative regulator of some, but not all, behavioral outcomes. 
Genetic loss of RGS4 or acute pharmacological inhibition of RGS4 with CCG-203769 increased 
the potency of SNC80 to produce antinociception and antihyperalgesia. The antinociceptive 
(acetic acid stretch assay), but not the antihyperalgesic effects of SNC80 were blocked by 
pretreatment with the peripherally-restricted opioid antagonist N-methylnaltrexone, suggesting 
peripheral DORs likely mediate the antinociceptive actions of SNC80 in the acetic acid stretch 
assay while DORs in the CNS mediate SNC80-induced antihyperalgesia. These observations 
suggest that DOR co-localizes with RGS4 within various pain pathways and neurocircuits of the 
peripheral and central nervous systems to modulate DOR signaling and DOR-induced pain relief 
in vivo. It has been proposed that activation of DOR produces analgesia by attenuating substance 
P release in the dorsal horn of the spinal cord (Kouchek et al. 2013). It would be interesting to 
evaluate whether inhibition of RGS regulation of DOR would potentiate DOR-mediated 
inhibition of substance P release. 
 RGS4 was shown to play a complex role in regulating DOR-mediated antidepressant-like 
effects, depending on the type of assay employed. In both the forced swim and tail suspension 
tests, SNC80 produced U-shaped dose effect curves, such that larger doses of SNC80 (10 mg/kg 
in TST, 32 mg/kg in FST) failed to produce significant antidepressant-like effects. In the forced 
swim test, elimination of RGS4 shifted the entire U-shaped function to the left, indicating that 
RGS4 acts as a negative regulator of DOR-mediated antidepressant-like effects and any possible 
competing behaviors in this assay. However, loss of RGS4 activity had no significant effect on 
SNC80-induced antidepressant-like effects in the tail suspension test. It is unlikely that 
differences in receptor occupancy or efficacy requirement could account for this discrepancy, as 
similar doses of SNC80 produced antidepressant-like effects in both assays. The behavioral 
effects of SNC80 in these two assays may originate from separate brain regions, behavioral 
mechanisms, and/or signaling pathways that are differentially dependent on RGS4 regulation.  
 In contrast to the role of RGS4 in antinociception, antihyperalegsia, and antidepressant-
like effects in the FST, reductions in RGS4 did not alter the potency of SNC80 to induce 
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convulsions. Although DOR and RGS4 are both highly expressed in the hippocampus, the 
proposed origin site of convulsions (Simmons and Chavkin 1996; Chung et al. 2015), they may 
not be co-expressed in the same cells and, therefore, may not functionally interact. The fact that 
some potential therapeutic effects of DOR are significantly enhanced in heterozygote (+/R4) 
knockout mice while no changes to convulsion are observed even in homozygote (R4/R4) 
knockout mice, highlights the distinctiveness of the pathways that underlie these behaviors. 
 RGS proteins negatively regulate G protein signaling by binding Gα-GTP and 
accelerating Gα-mediated GTP hydrolysis which returns Gα to an inactive state. Loss of RGS 
function should prolong the lifetime of active Gα and increase downstream signaling. Consistent 
with this theory, this study demonstrated that loss of RGS4 potentiated DOR-mediated: 1) 
phosphorylation of ERK1/2 in mouse striatal tissue, 2) peripheral antinociception, 3) central 
antihyperalgesia, and 4) antidepressant-like effects measured in the FST, presumably due to 
prolongation of DOR-mediated G protein signaling and amplification of downstream second 
messengers. Therefore, it is likely that behaviors regulated by RGS4 are generated through a G 
protein signaling mechanism and that the convulsive effects of DOR agonists are not mediated 
by G protein signaling mechanisms.  
 To further explore regulation of DOR by G protein-dependent and -independent signaling 
mechanisms, Chapter III of this thesis evaluated the potency of SNC80 to produce 
antihyperalgesia, antidepressant-like effects, and convulsions in Gαo heterozygous knockout 
mice, Gαo RGS-insensitive heterozygous knock-in mice, as well as arrestin 2 and arrestin 3 
knockout mice. We found that Gαo and arrestins differentially regulate the antihyperalgesia, 
antidepressant-like effects, and convulsions produced by the DOR agonist SNC80. The potency 
of SNC80 to produce antihyperalgesia and antidepressant-like effects in the forced swim test was 
significantly increased in the Gαo RGS-insensitive heterozygous mice. These data indicate DOR-
mediated antihyperalgesia and antidepressant-like effects signal through Gαo and are negatively 
regulated by RGS proteins, consistent with observations from Chapter II that RGS4 negatively 
regulates these behaviors. Interestingly, the magnitude of these behavioral changes are similar in 
RGS4 knockout and Gαo RGS-insensitive heterozygous mice, suggesting that other RGS 
proteins may not play a significant role in regulating the antihyperalgesic and antidepressant-like 
effects of DOR. Furthermore, SNC80-induced antihyperalgesia was abolished in Gαo 
heterozygous knockout mice, suggesting that Gαo plays a critical role in mediating signaling 
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required for DOR-mediated antihyperalgesia. Conversely, decreased expression of Gαo did not 
affect DOR-mediated antidepressant-like effects in the forced swim test. It is possible that DOR 
can signal through other G proteins in order to produce antidepressant-like effects and 
compensate for the reduction in Gαo expression. Alternatively, the efficacy requirement for 
DOR-mediated antidepressant-like effects may be relatively low compared to that for DOR-
mediated antihyperalgesia in which case one functional copy of GNAO1 and approximately 50% 
of Gαo protein subunits (Lamberts et al. 2011) could be sufficient to produce a full response in 
the forced swim test. This hypothesis is consistent with results from experiments described in 
Chapter IV, which concluded that the efficacy requirement for DOR-mediated antidepressant-
like effects is relatively lower than that for DOR-mediated antihyperalgesia. Taken together, 
these data suggest that DOR-mediated antihyperalgesia and antidepressant-like effects in the 
forced swim test signal through Gαo and are selectively regulated by RGS4. Future studies 
should evaluate the role of Gαo and other RGS proteins in regulating SNC80-induced 
antidepressant-like effects in the tail suspension test. 
 Because DOR-mediated convulsions were not altered in RGS4 knockout, Gαo 
heterozygote RGSi, or Gαo heterozygote knockout mice, we evaluated the hypothesis that 
convulsions are produced by a G protein-independent, arrestin-mediated signaling mechanism. 
No significant changes in DOR-mediated behaviors, including convulsions, were observed in 
arrestin 3 knockout mice. However, we did observe that the antinociceptive effects of morphine 
in the hot plate test were enhanced in arrestin 3 knockout mice, consistent with the findings of 
Bohn et al. (1999). Our observations with SNC80 are similar to previous reports showing that 
loss of arrestin 3 in mice did not alter the acute antihyperalgesic effects of DOR agonists in mice 
with CFA-induced inflammation and had no effect on the coupling of DOR to voltage-dependent 
calcium channels (Pradhan et al. 2013; Pradhan et al. 2016). These data are the result of acute 
administration of SNC80 and the possibility that arrestin 3 could play a role in regulating the 
effects of repeated doses of SNC80 should be explored in the future. Nevertheless, these findings 
indicate that arrestin 3 does not play a role in the acute behavioral effects of DOR. 
 In arrestin 2 knockout mice, we observed no changes in SNC80-induced antihyperalgesia 
or antidepressant-like effects; however, the potency of SNC80 to induce convulsions was 
enhanced, suggesting that arrestin 2 acts as a negative regulator of DOR-mediated convulsions. 
Interestingly, many arrestin 2 knockout mice convulsed multiple times in response to a single 
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dose of SNC80 despite the fact that under normal circumstances tolerance to the convulsive 
effects of DOR develops acutely and is long lasting (Comer et. al 1993; Hong et al. 1998). One 
possible explanation for this observation is that loss of arrestin 2 produces these behavioral 
changes by upregulating DOR trafficking to the cell membrane resulting in enhanced DOR 
signaling (Mittal et al. 2013). However, arrestin 2 and 3 expression is believed to be ubiquitous 
(Gurevich and Gurevich 2006), so if loss of arrestin 2 results in enhanced DOR membrane 
expression, all DOR-mediated behaviors would likely be affected and DOR-mediated 
antihyperalgesia and antidepressant-like effects were not significantly altered in arrestin 2 
knockout mice. Alternatively, arrestin 2 could be necessary for the rapid desensitization and 
tolerance to the convulsive effects of SNC80. Thus, loss of arrestin 2 could allow signaling 
pathways that would normally be terminated to persist and produce multiple convulsive events.  
The behavioral effects of repeated dosing of SNC80 should be evaluated to assess the role of 
arrestin 2 in the development of tolerance to the effects of DOR agonists. A third possibility, 
related to the second, is that arrestin 3 is not required for the initiation of a convulsion but is 
involved in signaling events that sustain convulsive activity. Although class A GPCRs 
preferentially interact with arrestin 3 (Oakley et al. 2000), arrestin 2 expression in neurons has 
been shown to be up to 20 times greater than arrestin 3 expression (Gurevich et al. 2004). It is 
possible that arrestin 2 exerts a protective role in neurons and prevents multiple convulsive 
events by outcompeting arrestin 3 for binding to DOR. Thus, when arrestin 2 is lost, arrestin 3 
dominates and allows for the production of multiple convulsive events. This hypothesis could be 
evaluated by determining if overexpression of arrestin 3 mimics the effects produced by a loss of 
arrestin 2. 
 Overall, these studies demonstrate a role for RGS4 and Gαo, but not arrestins, in 
regulating the acute antihyperalgesic and antidepressant-like effects of DOR. However, DOR-
mediated convulsions appear to be negatively regulated by arrestin 2 and are not altered by 
manipulations to RGS4 or Gαo function. Taken together, these findings suggest that different 
signaling pathways underlie the convulsive effects of DOR relative to the antihyperalgesic and 
antidepressant-like effects. This apparent functional selectivity in the DOR system may explain 
the existence of DOR agonists that do not produce convulsions at doses far exceeding those 
needed to produce antinociception and antidepressant-like effects (Le Bourdonnec et al. 2008; 
Saitoh et al. 2011; Chung et al. 2015). These agonists may be biased in such a way as to 
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preferentially activate signaling pathways regulating the so-called therapeutic effects of DOR. 
However, the properties of DOR agonists that determine their convulsive nature remain unclear. 
Future studies should continue to investigate the signaling mechanisms responsible for the 
behavioral effects of DOR agonists. 
 
Dissociating the Behavioral Effects of DOR Agonists: Efficacy and Receptor 
Populations 
  Chapter IV of this thesis explored the hypothesis that differences in the regulation of 
DOR-mediated behaviors by intracellular signaling partners is due to different efficacy 
requirements and/or receptor populations. We began exploring the pharmacological 
characteristics differentiating the behavioral effects of DOR agonists by evaluating the potency 
and effectiveness of the DOR partial agonist BU48 to produce DOR-mediated antihyperalgesia, 
antidepressant-like effects and convulsions. BU48 has previously been shown to elicit DOR-
mediated convulsions, but not DOR-mediated antinociception in NIH Swiss mice (Broom et al., 
2000). In C57BL6 mice, BU48 produced dose-dependent increases in convulsion severity with 
similar potency and efficacy to SNC80. Unlike with SNC80, mice treated with 3.2 mg/kg BU48 
exhibited some preconvulsive behavior, such as head twitches and brief myoclonic jerks.  
 BU48 also produced antidepressant-like effects in the forced swim test with reduced 
potency relative to SNC80. The apparent difference in observed efficacy in these behavioral tests 
between BU48 and SNC80 may be due to differences in intrinsic efficacy at DOR and/or the 
combination of DOR agonism with some KOR agonist properties of BU48. It is somewhat 
surprising that BU48 produces antidepressant-like effects despite being equipotent at DOR and 
KOR and more efficacious at KOR in vitro (Broom et al. 2000). Perhaps BU48 could be a useful 
pharmacological tool for evaluating the relative efficacy requirements for DOR-mediated 
antidepressant-like effects and KOR-mediated prodepressant-like effects. Ex vivo, BU48 did not 
significantly stimulate 35[S]GTPγS binding in forebrain tissue. This finding suggests that BU48 
is a low efficacy agonist, at least at the level of G protein activation, or engages G protein-
independent signaling pathways. 
 In the NTG-induced thermal hyperalgesia assay, BU48 not only failed to produce 
antihyperalgesia in wild-type mice, it antagonized SNC80-induced antihyperalgesia. Although it 
is possible that BU48 is a biased agonist incapable of activating the intracellular signaling 
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mechanisms needed to produce antihyperalgesia, BU48 did produce mild antihyperalgesia in 
RGS4 knockout mice. Because RGS4 acts as a negative regulator of Gαi/o signaling this 
observation suggests that the inability of BU48 to produce antihyperalgesia is due to insufficient 
efficacy and that BU48 is capable of producing antihyperalgesia via a SNC80-like mechanism. 
Taken together, these data strongly suggest that BU48 is a DOR partial agonist. A partial agonist 
should more readily produce low efficacy-requiring behaviors as compared to behaviors with 
higher efficacy requirements. Therefore, the ability of BU48 to produce DOR-mediated 
convulsions with potency comparable to a full agonist is consistent with convulsions having a 
low efficacy requirement. Furthermore, BU48 producing antidepressant-like effects with inferior 
potency and failing to generate antihyperalgesia on its own indicates that these behaviors have 
higher efficacy requirements relative to convulsive effects. 
 To further evaluate the role of efficacy requirements and receptor reserve in DOR-
mediated behaviors, the potency of SNC80 to produce antihyperalgesia, antidepressant-like 
effects, and convulsions was evaluated in DOR heterozygous knockout mice (Receptor 
densities— +/+: 105 ± 7 fmol/mg; +/-: 42 ± 3 fmol/mg). The potency of SNC80 to elicit all three 
of these behaviors was significantly reduced in DOR heterozygous knockout mice, with the 
following rank order of efficacy requirement: convulsive effects < antidepressant-like effects < 
antihyperalgesia. SNC80 did not produce any of these behaviors in DOR homozygous knockout 
mice, further validating the idea that these behaviors are specifically mediated by DOR.  
 The effect of changes in DOR number on DOR-mediated behaviors was also investigated 
using the irreversible antagonist 5’-NTII. Consistent with the potency changes observed in DOR 
heterozygous knockout mice, a 30% reduction in DOR number was sufficient to decrease the 
potency of SNC80 to produce antihyperalgesia and antidepressant-like effects. However, this 
small decrease in DOR number failed to shift the convulsion dose response curve. The minimal 
inhibition of SNC80-induced convulsions following reduction in DOR number of either 30% or 
60% suggests that convulsions have a large receptor reserve. Therefore, few receptors would 
need to be activated in order to produce convulsions. Consequently, DOR-mediated convulsions 
likely have a low efficacy requirement. Conversely, SNC80-induced antihyperalgesia was quite 
sensitive to reductions in DOR number suggesting a low receptor reserve and high efficacy 
requirement. The decrease in potency of SNC80-induced antidepressant-like effects was 
moderate, suggesting an efficacy requirement between that for convulsions and antihyperalgesia. 
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 Chapters II and II of this thesis demonstrated that DOR-mediated behaviors are 
differentially regulated by Gαo, RGS4, and arrestin 2. Specifically, SNC80-induced 
antihyperalgesia and antidepressant-like effects were potentiated in RGS4 knockout mice and in 
Gαo RGS-insensitive knock-in mice. In addition, SNC80-induced antihyperalgesia was abolished 
Gαo heterozygous knockout mice, but antidepressant-like effects were unaffected. However, 
SNC80-induced convulsions were unaltered in those transgenic mouse strains and potentiated in 
arrestin 2 knockout mice. We hypothesized that these observations could reflect functional 
selectivity within the DOR system and that convulsions may be mediated by distinct signaling 
pathways relative to the antihyperalgesic and antidepressant-like effects. 
 The results described in Chapters II and III of this thesis are also consistent with the 
alternative hypothesis presented in Chapter IV that differential regulation of DOR-mediated 
behaviors is due to differences in the efficacy requirements of those behaviors. For example, the 
efficacy requirement for DOR-mediated convulsions may be so low that they are unaffected by a 
loss of RGS regulation or a 50% reduction in Gαo. The efficacy requirement for antidepressant-
like effects may be high enough so as to be under regulation of RGS proteins but still low 
enough that 50% of Gαo expression is sufficient to produce a normal response. Finally, the 
efficacy requirement for antihyperalgesia would be so high that it is affected by both RGS 
regulation and a 50% loss of Gαo. 
 Interestingly, the DOR competitive antagonist NTI shifted the dose response curves of 
DOR-mediated behaviors to different degrees. Although we did not test enough doses to perform 
a full pA2 analysis, our data still suggest that NTI antagonizes DOR-mediated behaviors with 
distinct potencies. For example, 1 mg/kg NTI was sufficient to completely block 
antihyperalgesia produced by 10 and 32 mg/kg SNC80 but did not affect convulsions produced 
by SNC80 at either of those doses. These differences in antagonist potencies across separate 
behavioral endpoints suggest that different receptor populations mediate these behaviors. There 
are several possibilities regarding what these different receptor populations represent. The 
putative DOR(1) and (2) subtypes may mediate different behavioral effects of SNC80 (Pacheco 
et al. 2005; Rawls et al. 2005). Delta-mu and delta-kappa receptor heterodimers that engage 
unique signaling mechanisms to produce distinct behaviors relative to their monomeric 
counterparts have been proposed (Jordan and Devi 1999; Rozenfeld and Devi 2007). Differences 
in the subcellular localization or internalizing properties of DORs could lead to differences in 
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downstream signaling (Pradhan et al. 2009). It is well accepted that different DOR-mediated 
behaviors are generated by distinct brain regions. For example, DOR-mediated analgesia is 
governed by the dorsal horn (Cahill et al. 2003) and PAG (Ossipov et al. 1995) while DOR-
mediated convulsions originate in the hippocampus (Simmons and Chavkin 1996). However, 
DOR subpopulations may exist within these distinct brain regions with variations in G protein 
expression, subtypes, or coupling efficiency. Alternatively, these distinct receptor populations 
could also represent differences in the times at which these behaviors can be observed. If these 
distinct DOR populations are identified, it would be interesting to investigate in future studies 
whether they are differentially regulated by proteins such as RGS4, Gαo, and arrestins. 
 In summary, these data suggest that DOR-mediated behaviors have distinct efficacy 
requirements with convulsions having the lowest efficacy requirement, followed by 
antidepressant-like effects and antihyperalgesia, respectively. Furthermore, these DOR-mediated 
behaviors are likely governed by distinct receptor populations as evidenced by the DOR 
competitive antagonist NTI attenuating DOR-mediated behaviors with different potencies. 
 
Dissociating the Behavioral Effects of DOR Agonists: Nonconvulsive Delta 
Agonists 
 As described in the introduction of this thesis, multiple DOR agonists have already been 
developed that do not produce convulsions when given systemically in large doses (Naidu et al., 
2007; Vergura et al., 2008; Le Bourdonnec et al., 2008; Saitoh et al., 2011). If indeed the 
efficacy requirement for convulsions is low, it is critical to determine why these agonists do not 
produce convulsions. It is possible that these nonconvulsive DOR agonists are biased in such a 
way as to not produce convulsions. For example, these drugs may be unable to activate the DOR 
populations responsible for convulsions or may selectively activate different intracellular 
signaling mechanisms downstream of DORs. Alternatively, the pharmacokinetic properties of 
these drugs could inhibit their ability to produce convulsions. It has been shown that rapid 
intravenous infusion of SNC80 improves its potency to produce convulsions while slow (20 or 
60 min) infusions of SNC80 greatly diminishes potency (Jutkiewicz et al., 2005). Nonconvulsive 
DOR agonists could be absorbed more slowly, thus preventing the onset of a convulsion.  
 To begin to address these possibilities, we evaluated the behavioral effects of the 
nonpeptidic DOR agonist KNT-127 (See Appendix). In C57BL6 wild-type mice, KNT-127 
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produced DOR-mediated antihyperalgesia and DOR-mediated antidepressant-like effects with 
similar potency to SNC80 (Figures A.1-A.4). Consistent with previous reports, KNT-127 did not 
produce convulsions at doses of at least 32 mg/kg sc (Figure A.5; Saitoh et al. 2011). KNT-127 
also did not produce convulsions when administered intravenously (iv) at doses up to 10 mg/kg, 
suggesting that the discrepancies in the convulsive properties of KNT-127 and SNC80 are likely 
not due to differences in absorption or distribution. It is possible that KNT-127 could produce 
convulsions if given directly into the brain, however we were unable to produce convulsions in 
mice given intracerebroventricular injections of SNC80 (data not shown).  
 To explore the hypothesis that KNT-127 is biased in such a way that it does not activate 
the signaling mechanisms needed to produce convulsive effects, we examined the effects of 
KNT-127 pretreatment on SNC80-induced convulsions. If KNT-127 engages the same receptor 
populations and receptor binding sites as SNC80 but is biased against convulsive effects, it 
should antagonize SNC80-induced convulsions. However, pretreatment with 10 mg/kg KNT-127 
did not block convulsions produced by 10 mg/kg SNC80 (Figure A.6). It is possible that larger 
doses of KNT-127 are needed to inhibit SNC80-induced convulsions and this should be 
evaluated in the future. Another possibility is that KNT-127 does not interact with the DOR 
population responsible for convulsions. However, KNT-127 did reduce the dose of the chemical 
convulsant PTZ needed to produce convulsions (Figure A.7). Although these data suggest that 
KNT-127 does have some convulsive properties, the DORs responsible for enhancing PTZ-
induced convulsions may be distinct from those that mediate SNC80-induced convulsions. In 
support of this hypothesis, it was recently shown that loss of DOR expression in GABAergic 
forebrain neurons was sufficient to prevent SNC80-induced convulsions and EEG disturbances, 
however PTZ produced similar convulsive effects in these transgenic mice and wild-type 
controls (Chung et al. 2015). Taken together, these data may suggest that KNT-127 does not 
produce convulsions on its own because it does not activate the receptor population responsible 
for DOR-mediated convulsions. This hypothesis could be tested by comparing the potencies of 
SNC80 and KNT-127 to activate G protein across different brain regions using GTPγS 
autoradiography. Future studies should further evaluate the nature of these distinct receptor 






 DOR agonists produce a number of behavioral effects, including antihyperalgesia, 
antidepressant-like effects, and convulsions. These behavioral effects are differentially regulated 
by multiple signaling molecules such as RGS4, Gαo, and arrestin2. These behavioral effects also 
display the following rank order of efficacy requirement: convulsions < antidepressant-like 
effects < antihyperalgesia. Distinct populations of DORs may mediate these different behavioral 
effects and it is possible that DOR agonists differentially activate these receptor populations. 
Future studies should continue to examine the nature of these distinct DOR populations. Future 
work should also investigate where the signaling molecules that differentially regulate DOR-
mediated behavior exert their effects. For example, it would be interesting to investigate whether 
loss of RGS regulation of DOR or Gαo expression specifically in the dorsal horn and/or PAG 
affected DOR-mediated analgesia. In further exploring the mechanisms responsible for DOR-
mediated antidepressant-like effects, the effect of RGS4 and Gαo function on BDNF and 
glutamate release should be examined. Overall, the work presented in this thesis should benefit 
the production of safer DOR agonists with improved clinical utility. The possibility of 
pharmacologically targeting receptor populations or signaling pathways responsible for DOR-
mediated analgesic and antidepressant-like effects without activating receptors that mediated 
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Figure A. Characterization of KNT-127-induced behaviors in C57BL6 wild-type mice. (1) 
Effects of different doses of KNT-127 or SNC80 on tail withdrawal latencies in NTG-treated 
mice. (2) Effect of NTI on KNT-127-induced increases in tail withdrawal latency in NTG-treated 
mice. (3) Effects of different doses of KNT-127 or SNC80 on immobility scores in the forced 
swim test. (4) Effect of NTI on KNT-127-induced decreases in immobility in the forced swim 
test. (5) Effects of route of administration on KNT-127- and SNC80-induced convulsive effects 
(6) Effects of KNT-127 on SNC80-induced convulsions (7) Effects of different doses of KNT-
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